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Abstract 
 
 
Vascular remodelling and angiogenesis are commonly associated with sight 
threatening diseases such as age related macular degeneration (AMD) and diabetic 
retinopathy. Current treatments for retinal vascular pathology are limited to inhibitors 
of potent growth factors such as vascular endothelial growth factor (VEGF), which 
despite preventing any further vascular growth cannot mend the damage already 
done. Vascular abnormalities are associated with late stages of disease, meaning we 
are treating patients too late. We must identify new, earlier therapeutic tagets to 
preserve vision. 
  
Gene expression profiling was performed on retinal vessels isolated from three 
mutant mouse strains (Curlytail, VLDLR-/- and RD1) that display retinal vascular 
abnormalities. Sixty-two genes were found to change in all three models. One gene 
which was significantly up-regulated was LBP (lipopolysaccharide binding protein). 
This is an acute-phase response glycoprotein, which through its binding to LPS and 
activation of TLR4 is involved in inflammatory signalling.  
 
We have tested the hypothesis that LBP has a novel function separate from its 
characterised LPS recognition. qPCR analysis of VLDLR-/- mice has shown LBP to 
be expressed in the neuroretina and isolated vessels. qPCR data has shown LBP to be 
up-regulated in VLDLR-/- mice just prior to an increase in VEGF expression and the 
vascular abnormalities being observed. Testing LBP affects in Matrigel, Aortic ring 
and Metatarsal assays revealed an increase in vessel sprouts and branching. Western 
blot analysis has suggested LBP can induce phosphotyrosine and phophoERK 
responses in a variety of cell lines and immnocytochemistry data provides evidence 
that this is not occuring through the well-established LBP-LPS NfkB pathway. PCR 
analysis of older passage HUVEC which are unresponsive to LBP has given us a 
candidate receptor.  
 
In conclusion, we have revealed a potential role for LBP in contributing to 
angiogenesis. 
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Introduction 
 
 
1. The Eye 
1.1 Function and Anatomy 
Our eyes detect light and help us to interpret the world in which we live. The white 
light surrounding us contains a blend of coloured wavelengths. When light hits an 
object some of the coloured wavelengths are absorbed whilst others are reflected. 
This reflected light then effectively carries information about the object it has 
touched. When light reaches our eyes it is defracted by the cornea, passes through the 
pupil, is defracted once more by the lens, passes through the vitreous humour and 
then reaches the retina, a layer of cells lining the back of the eye, approx 42mm in 
diameter and 0.1-0.3mm thick (depending on where in the tissue the measurement is 
made, fovea 0.1mm, foveal rim 0.23-0.32mm) [1]. 
 
The retina contains endothelial cells, neuronal cells, glial cells, retinal pigment 
epithelium (RPE) and two specialised photoreceptors called rods and cones, which 
detect light via the visual pigment retinal embedded in their bilipid membranes 
(figure 1). Rod cells function at low light intensity to give us vision in darker 
conditions as well as shadow perception. Cone cells are responsible for our colour 
vision, they can be sub-divided into three types able to detect different light 
wavelengths of red, blue and green colour. The ability of cone cells to detect different 
wavelengths depending on what form of opsin protein combines with the retinal 
pigment [1]. The placement of rods and cones throughout the retina is highly variable 
depends on species, but in primates cone cells are more prevalent in the central 
regions with a greater proportion of rods in the periphery [2].  
 
There is a structure in the primate retina, adjacent to the optic nerve head called the 
macula. The macula has a central region known as the fovea, which contains the 
highest percentage of cone cells in the retina. This results in the fovea being a vitally 
 18 
important region for central vision and acuity, a retinal characteristic unique to 
humans and other primates [1-3]. The macula also has a high concentration of 
xanthophyll pigments called lutein and zeaxanthin [4]. Xanthophylls cannot be 
synthesised by the body and so have to be obtained through a diet rich in certain 
vegetables such as leafy green vegetables and yellow/orange peppers. The exact 
function of macular pigment is still not fully understood, but being enriched in the 
Henle fibre layer adjacent to the foveal photoreceptors, it is thought to have a photo-
protective role [5]. The eye is susceptible to oxidative damage due to its frequent 
light exposure and the high concentration of polyunsaturated fats in receptor 
membranes [6]. The macular pigment is thought to help filter out damaging 
wavelengths (especially blue light) thus preventing oxidation and reactive oxygen 
species (ROS) such as hydrogen peroxide from forming in the photoreceptor layers 
[7]. When the photoreceptors capture light, they translate the information into an 
electrical signal, which can then be transmitted by the neuronal cells within the retina 
to the optic nerve and then onto the brain for processing [3]. The output information 
is what we define as vision. Sight is incredibly important to us. It enables us to 
observe and assess the world around us so we can interact accordingly. When there is 
a problem with our sight it can be seriously disabling, demand huge adaptations of 
our behaviour and force us to develop coping mechanisms that rely on our other 
senses. 
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Figure 1: Schematic of a Human Eye. Drawing of a sagittal slice through an eye with magnification 
of the retinal cells. Inner limiting membrane (ILM), Amacrine cells (AC), Bipolar cells (BP), 
Photoreceptor (PR), Retinal pigment epithelium (RPE). Taken from WebVision resource 
http://webvision.med.utah.edu/book/part-i-foundations/simple-anatomy-of-the-retina/ 
 
 
1.2 Blood Supply  
The retina receives blood from two sources. The majority (65-85%) comes from the 
choroidal blood vessels of the choriocapillaris behind the eye. This supply is 
particularly important for supporting the outer retina. The remaining 20-30% comes 
from the central artery, which originates through the optic disc, fans out across the 
retina and splits into three capillary networks (figure 2). This splitting enables blood 
and nutrients to reach and sustain all of the inner retinal layers. The vessel 
distribution within the retina has resulted in the three layers being termed ‘superficial 
vessels’, ‘intermediate vessels’ and the ‘deeper vessel plexus’. The radial 
peripapillary capillaries (RPCs) make up the superficial layer as they share the 
pathways of the major vessels found 4-5mm from the optic disk. The deeper layer of 
capillaries runs parallel to the RPCs in the ganglion cell layer and connects to the 
RPCs through anastomosis [8]. The macula and fovea receive a limited blood supply 
from the superior and inferotemporal arteries, but have no vessel network within, in 
order to enable high acuity central vision [3]. 
 
Figure 2: Blood Supply to the Eye. Drawing shows the two blood supplies to the eye displaying the 
choroidal perfused layers and the three inner retinal vessel layers. Taken from the NHS Scottish 
diabetic screening services handbook http://www.ndrs.scot.nhs.uk/Train/Handbook/drh-06.htm 
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2. Angiogenesis  
Angiogenesis is the generation of new blood vessels from a pre-existing vessel bed or 
network. It occurs as a normal process important in the body for development and 
wound healing, however pathogenic angiogenesis is a major contributing factor to 
diseases [9] such as growth or metastatic dissemination of solid tumours, and also 
proliferative diabetic retinopathy and the neovascular ‘wet’ form of age related 
macular degeneration (AMD) [10].  Angiogenesis can be divided into different sub-
types depending on the mechanism of vessel generation [11].  
 
1. Vasculogenesis occurs in early embryonic development and refers to do novo 
vessel development via differentiation of endothelial precursor cells.  It can be 
divided into extraembryonic and intraembryonic blood vessel formation, which are 
spatially and temporally distinct processes. Growth factors such as fibroblast growth 
factor-2 (FGF2), bone morphogenetic proteins (BMPs), downstream SMAD targets 
have been identified as having key in vasculogenesis and vascular endothelial growth 
factor (VEGF)[12]. 
 
VEGF is a potent promoter of both vessel growth and vessel permeability, which is 
another problem in eye disease [13-15]. Five isoforms of the growth factor are 
produced through alternate splicing of its eight exons and seven introns, namely 
VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-E. VEGF-A is the major isoform 
and the one of interest concerning angiogenesis [16]; it exists in three splice variants, 
these being VEGF 121, 165 and 189 (figure 3), each of which can be alternatively 
spliced into antiangiogenic ‘XXXb’ variants [16]. All VEGF-A variants have been 
found to contain exons one to five but vary in their six to eight content. Exons six and 
seven encode for the C terminus and regulate the affinity of VEGF isoforms for 
heparan sulfate proteoglycans (HSPGs). VEGF121 lacks the binding motifs in its C-
terminus, meaning it does not bind to HSPGs on the extracellular matrix or cell 
surface, which makes it readily diffusible. VEGF165 has partial binding so is weakly 
sequestered by HSPGs, and VEGF189 has high affinity for HSPGs so remains 
sequestered until cleaved [17]. As well as HSPGs, VEGF-A isoforms have been 
shown to bind to Neuropilin-1 (Np-1) and two high affinity VEGF receptors, 
VEGFR1 (also known as Flt-1) and VEGFR2 (Flk-1). VEGFR1+2 share 44% 
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sequence homology and are both transmembrane tyrosine kinase receptors [18]. 
VEGF is an important growth factor in vascular development and restructuring of 
blood vessel networks under hypoxic conditions [18, 19]. VEGFR2 mediates most of 
the biological activities of VEGF-A [20], this VEGF binding to VEGFR2 induces 
receptor dimerisation and autophosphorylation to generate sites for Src homology 2 
(SH2) domain containing protein (e.g. Grb2) recruitment. After docking on SH2 sites 
these proteins are phosphorylated to induce further signal transduction of 
proliferative pathways like the Raf1/MEK/ERK cascade [21]. VEGFR2 deficient 
mice have been reported to die at embryonic age 8.5-9.5 as a consequence of a lack 
of vascularisation demonstrating the critical role of VEGFR2 in VEGF angiogenic 
signalling [22]. VEGFR1 also has high affinity for VEGF-A but appears to behave as 
a decoy receptor, inhibiting the signalling effects of VEGF. It can however have 
angiogenic effects through binding and signalling of placental growth factor 
(PlGF)[103]. Mice deficient in VEGFR1 also die at E8.5-9.5 but show a 
hyperactivity of VEGF signalling, consistant with the idea that the receptor is 
required for negative regulation of VEGF [13, 18]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Vascular Endothelial Growth Factor (VEGF) Signalling. Schematic to show the activity 
of the different isoforms of VEGF, their receptor interactions and physiological effects. Neuropilin 1 
and 2 (Nrp-1 and Nrp-2), Placental growth factor (PlGF). Taken from Paul Scherrer Institut Prota lab 
page http://sb.web.psi.ch/projects/neuropilin.html 
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2. Sprouting angiogenesis (figure 4) occurs throughout adulthood and refers to the 
generation of new blood vessels from pre-existing capillary networks. The process is 
vital for supporting expansion of new tissue and wound healing, but if not well 
controlled can contribute to diseases such as cancer and rheumatoid arthritis [23]. 
Sprouting angiogenesis is initiated by growth factor (FGF, VEGF, PlGF and 
angiopoietin 1) stimulation of neighbouring vascular support cells (e.g. pericytes, 
smooth muscle cells) and endothelial cell surface receptors. This leads to production 
of matrix metalloproteinases (MMPs) that break down the surrounding extracellular 
matrix and basement membrane thus allowing the endothelial cells to proliferate and 
invade the surrounding tissue, with cell polarity establishing a vessel lumen [23, 24]. 
VEGF is thought to be the key regulator of sprouting angiogenesis, acting as a 
guidance factor for the specialised tip endothelial cells, and as a proliferative inducer for 
the endothelial stalk cells within the vessel [11, 23, 25]. 
 
 
 
Figure 4: A Schematic of Sprouting Angiogenesis. Chronological representation of the events 
thought to drive sprouting angiogenesis. a) Angiogenesis is regulated with a tight balance between 
pro-angiogenic and anti-angiogenic factors. Some endothelial cells will respond (green) whereas some 
will not (grey). b) The growing cell sprout is guided by a VEGF gradient with tip cells releasing 
platelet-derived growth factor (PDGF) recruiting pericytes (yellow). c) When tip cells contact there are 
either attractive or repulsive cues present to regulate fusion. d) Tip cell fusion establishes a luminal 
space, allows blood flow and thereby removes hypoxic initiation of further angiogenesis. [11] 
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3. Intussusceptive angiogenesis (also known as splitting angiogenesis) is a specialised 
remodelling process which follows four growth steps (figure 5) – 1) Opposing walls 
of the vessel lumen protrude, generating a contact point for the endothelial cells. 2) 
Intracellular junction proteins reorganise to join the contacted cells together. 3) 
Supporting cells (e.g. pericytes and myofibroblasts) deposit matrix proteins for the 
cellular network. 4) The generated vessel pillar increases in size to create a thicker 
vascular pillar [25, 26].  
 
Three different variants of intussusceptive angiogenesis have been reported, which 
vary in the angle of their pillar generation. Intussusceptive microvascular growth 
expands the capillary plexus via production of transluminal pillars. Intussusceptive 
arborisation splits the plexus with vertical pillars to generate ‘feeding’ vessel 
networks. Intussusceptive branching does not generate new vascular tissue but by 
inserting vertical pillars at vascular branch points it enables remodelling of the vessel 
network. The underlying mechanism for intussusceptive angiogenesis is not 
understood but studies in mice have shown Ang1, VEGF, transforming growth factor 
ß (TGFß) and Notch4 signalling to be required for vascular remodelling similar to the 
variants of intussusceptive angiogenesis [25, 26].  
 
Figure 5: A Schematic of Intussusceptive Angiogenesis. Diagram to show the nature of splitting 
angiogenesis. The generation of tissue pillars enables the vessel to branch, the molecular mechanisms 
involved are not currently known but thought to involve cell proliferation, migration, degradation of 
extracellular matrix (ECM) and deposition of new ECM. [11]  
 
 
3. Diseases of the Retinal Vasculature  
It is estimated that every 15 seconds someone, somewhere in the world loses their 
vision [27]. This is an alarming statistic and one which needs addressing. The variety 
of cell types within the eye means that a complex functional interplay needs to be 
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maintained in order to sustain a healthy retina. If one cell type becomes dysfunctional 
or diseased it can have a knock-on effect for the entire visual system ultimately 
resulting in a threat to vision. There are numerous examples of retinal diseases that 
have their origins in photoreceptor death (e.g. retinitis pigmentosa) or elevated ocular 
pressure (glaucoma), however the focus of this thesis is retinal vascular disease so I 
will concentrate on conditions where vascular abnormalities are a major contributor 
to clinical symptoms and disease progression.  
 
3.1 Age related Macular Degeneration (AMD) 
AMD is one of the most common eye diseases, causing degenerative blindness in 
patients over 50 years of age. AMD can be divided broadly into two types; atrophic 
(‘dry’) and neovascular (‘wet’).  Atrophic AMD is far more common (approximately 
90% of patients) than neovascular (10%). Generally patients with atrophic AMD 
experience less visual disturbance then patients with neovascular disease, however 
this is not always the case as it depends on the severity and geography of drusen 
formation. Drusen are fatty deposits, which form at the interface of Bruch’s 
membrane and the RPE and are the first clinically detectable sign of AMD (figure 6). 
It is thought that increased oxidative damage to the photoreceptor layer produces 
waste products, which the RPE are unable to digest [28, 29]. This causes 
accumulation of waste in the RPE, altering their metabolism and stimulating them to 
secrete products basally, which collect and contribute to the formation of drusen [28, 
30]. It is known that there are different types of drusen; hard drusen appear as small 
discrete deposits containing tube-like vesicle structures and collagen, soft drusen tend 
to be larger with ill-defined boundaries containing membranous debris, semisolid 
drusen are a mixture of the two types, and calcified drusen appear to glisten upon 
examination [31, 32]. It is estimated that over 50% of the population >70yrs of age 
have drusen but report no visual disturbances [32]. Thus, drusen formation is not 
causative of disease itself, and may be considered part of normal healthy aging. 
However, the severity of vision loss appears to correlate with the number of drusen 
deposits and where they form. A high number of central drusen correlates with 
central vision impairment, and in general soft drusen are more detrimental than the 
other types [32, 33].  
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Atrophic AMD can develop into neovascular AMD upon the growth of new blood 
vessels from the choroidal plexus. The new vessel sprouts push through the Bruch’s 
membrane and invade the RPE layer where they leak and cause damage, promoting 
cell death. [34].  
 
Retinal angiomatous proliferation (RAP) is a distinct form of choroidal 
neovascularization that has been found to correlate to a poor disease prognosis. The 
exact cause remains unknown but research has shown it to have a higher prevalence 
in women and the elderly [35] and that its development is thought to occur over three 
stages: 1) intraretinal neovascularization where the deeper plexus intraretinal 
capillaries proliferate. 2) subretinal neovascularization where the growing vessels 
invade the subretinal space and 3) clinical manifestation where the RAP / CNV could 
be determined clinically [36]. 
 
There are two processes thought to provide the triggers for AMD onset, hypoxia and 
chronic inflammation. Bruch’s membrane naturally thickens with age, which is 
thought to gradually diminish diffusion of the nutrients from the blood supply into 
the retina, resulting in oxygen deprivation. This then promotes VEGF induction and 
blood vessel growth [37, 38]. Crucially AMD has been found to have a higher 
prevalence in patients with specific genetic variations in certain complement proteins 
[37, 38, 39]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Fundus Photograph of a Patient with AMD. Shows soft drusen (arrowed) formation 
within the retina. Taken from WebVision resource http://webvision.med.utah.edu/book/part-i-
foundations/simple-anatomy-of-the-retina/ 
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The complement system is part of the innate immune system. It consists of over 25 
circulating inactive proteins, receptors and proteases, which are activated upon 
infection to have cell killing affects. Complement factor H (CFH) is an important 
regulator of the complement cascade [40]. The Y402H polymorphism in CFH has 
been linked to an increase in the chances of developing AMD [40-43]. Thus, 50% of 
AMD patients are believed to have the Y402H polymorphism, in which a tyrosine 
residue is replaced with a histidine residue. The change occurs in the heparin and C-
reactive protein (CRP) binding sites, decreasing the affinity of CFH for its substrates 
[44]. This is thought to diminish or inhibit CFH function, thus sending complement 
into overdrive [32, 40]. It remains unclear exactly how this chronic signal activation 
is thought to drive disease pathogenesis but polymorphisms in other complement 
proteins such as factor B, C2 and C3 are also associated with AMD, confirming a 
causative link between immunity and the disease [39, 47]. The CFH Y402H variant is 
also thought to be linked to soft drusen formation as Japanese and Chinese AMD 
patients have decreased soft drusen formation as well as a lower prevalence of 
Y402H (<5%) whereas white Caucasian AMD patients have a higher soft drusen 
occurrence along with higher prevalence of Y402H (>35%). This observation 
suggests that ethnicity as well as the CFH polymorphism contribute to susceptibility 
to AMD [48]. Histopathology studies have demonstrated an increased presence of 
fibroblasts, macrophages and lymphocytes within Bruch’s membrane of AMD 
patient eyes, further supporting a link between immunity and the disease [49]. 
 
Other genetic alterations are also associated with AMD. Mutations affecting the 
activity of ABCA4, an ATP-binding cassette transporter of retinaldehyde, expressed 
in the photoreceptors have been linked to AMD [50-52] suggesting faulty 
photoreceptor function as a contributing factor. In addition, functional disruption to 
proteins involved in extracellular matrix remodelling (e.g. TIMP3, fibulins 5 and 6) 
have also been implicated [53].  As previously mentioned, due to its frequent light 
exposure the retina has high levels of oxidative stress. The generation of ROS 
through oxidative stress can be pathogenic if unbalanced as ROS damage all major 
cellular components, including DNA [54]. Faulty mitochondrial function and 
polymorphisms in deoxyribonucleic acid (DNA) base excision repair genes hOGG1 
and MUTYH, which repair ROS-induced damage to nucleic acids, have been 
identified in AMD patients, supporting increased oxidative damage as a contributing 
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factor to the progression of the disease [6]. There is still much debate over what 
causes the disease to progress from atrophic to neovascular; some work has 
suggested that a polymorphism in the promoter for the heat shock serine protease 
HTRA1 is required [55, 56]. The genetic alteration appears to increase the 
transcriptional affinity for the adaptor related protein complex 2a (A2a) and serum 
response factor (SRF), which is suggested to promote vascular growth. Interestingly 
expression of HTRA1 is up-regulated under oxidative stress, again supporting a link 
between this process and AMD [56]. 
 
Lifestyle choices, such as poor diet and smoking have also been shown to increase 
the chances of developing AMD. Smoking can harden the blood vessels so they 
become fragile or blocked. This fragility can lead to breakages and leakage of fluid 
into surrounding tissue. Moreover, venal obstruction may result in growth of new 
blood vessels to compensate for the oxygen deprivation caused by inadequately 
supported tissue. Studies have shown that smoking also increases ROS generation 
and the levels of CRP in circulating plasma, thus mimicking an immune response and 
inducing complement activation [6, 38]. It has been reported that neovascular AMD 
progresses four times faster in smokers than in non-smokers [6, 57]. 
 
A healthy diet is thus important for preventing disease. A decrease in the amount of 
macular pigment has been indicated as being associated with an elevated risk of 
AMD progression [5]. Adipose tissue has been found to sequester the pigments, 
implying that obesity may compromise the delivery of the protective pigments to the 
retina [57, 58]. 
 
 
3.2 Diabetic Retinopathy 
Diabetes mellitus is a common disease affecting over 2.8 million people in the UK 
alone [59]. There are two types of the disease, insulin dependent (IDDM) where the 
patient is unable to make any or enough insulin to metabolise glucose, and non-
insulin dependent (NIDDM) where the patient often makes enough insulin but their 
cells have become unresponsive to the hormone. A range of health complications 
accompanies diabetes, among which retinopathy is the most common. Thus, 80% of 
patients who have had IDDM for 10yrs will have retinopathy, and 20yrs of the 
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disease increases the likelihood to 95% [60-62]. Diabetic retinopathy is the leading 
cause of blindness in developed countries, affecting the working age population (20-
74yrs) and estimated to generate 12% of the annual cases of blindness [63]. 
 
Diabetic retinopathy can affect many cell types within the retina but it is 
characterised as a disease of the intraretinal blood vessels.  There are two types of the 
disease, non-proliferative and proliferative (figure 7). The non-proliferative form is 
the most common and is characterised by increased capillary permeability and 
basement membrane thickening [64]. Patients with non-proliferative diabetic 
retinopathy will sometimes remain asymptomatic depending on the severity and 
positioning of capillary leakage [64]. Diabetic patients show increased number and 
activation of leukocytes (leukostasis) [63]. Leukocytes are able to adhere to the 
endothelium via ICAM-1 interactions and have a capacity to secrete proteolytic 
enzymes [63], therefore leukostasis poses problems for the retinal microvasculature. 
In vivo observations have reported that vascular non-perfusion and leakage are 
temporally and spatially associated with intravascular leukocyte aggregation [65]. 
Proliferative diabetic retinopathy occurs as a result of the microvascular blockages 
threatening nutrient supply, inducing hypoxic conditions thus triggering 
neovascularisation into the surrounding tissue which causes damage, cell death and 
vision loss [64, 65]. 
Figure 7: Fundus Photography Representation of Diabetic Retinopathy. Shows the non-
proliferative stage and the proliferative disease with marked neovascularisation. Taken from the 
DPLEI Certified Hospital webpage patient resource http://www.drpattnaik.com/vitreo.html 
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The molecular aetiology of diabetic retinopathy is not completely understood but 
studies have shown that hyperlipidemia and hypertension contribute to the 
pathogenesis and that hyperglycaemia is the principle cause of disease in both IDDM 
and NIDDM [62-64]. It was suggested that better glucose control could offer some 
protection from disease onset, but studies using diabetic dogs and rats with long-term 
regulated glucose levels followed by a short period of poor glucose control, 
demonstrated that long-term glucose management offered little protection [65, 66]. It 
is thought that the disease stems from a series of long term metabolic alterations in 
the retinal cells. Free amine groups found on proteins, nucleic acids and lipids 
undergo reversible non-enzymatic reactions to generate intermediate products known 
as Schiff bases and Amadori products. When glucose is low these products can be 
broken down to re-establish sugar groups and maintain an energy balance in the cell. 
When there is a high glucose concentration the products can be stored or undergo 
further modification to keep the sugars sequestered, however after a series of 
modifications the products will form AGEs [66]. This reaction balance means that 
diabetic patients will tend to have a higher concentration of AGEs, which in turn may 
covalently crosslink proteins, lipids and DNA altering their structure and behaviour 
[64, 67-69].   
 
Generation of advanced glycation end-products (AGEs) and de novo synthesis of 
diacylglycerol (DAG) leading to overactivation of various protein kinase C (PKC) 
isoforms and the renin-angiotensin system (RAS) could contribute to retinal vascular 
pathogenesis [64, 73, 74]. Some receptors for AGEs have been identified with the 
most well characterised existing as a triple complex (R1, R2 and R3) called RAGE 
[66, 74]. The signalling capacity of AGEs is not well defined but has been suggested 
to induce PKC, Janus Kinase (JAK), signal transducers and activators of transcription 
(STAT), nuclear factor kappa ß (NF-kß) and AP1 [76]. 
 
The role of AGEs in retinopathy remains unclear but there has been insight into their 
contribution to renal disease as they have been found to induce transforming growth 
factor-ß (TGFß) [75, 77] and diabetic mice that do not express galectin-3 (the R3 
component of RAGE) are protected against diabetic nephropathy [64, 79]. In vitro 
experiments have shown that treatment of endothelial cells with preformed AGEs 
induces proliferation, caused by an induction of VEGF [80]. This has also been 
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shown to occur in vivo with acute elevation of AGEs, however long term exposure to 
AGEs appears to inhibit vessel proliferation [64]. Four polymorphic alterations in the 
RAGE promoter have been identified, altering the transcription and expression of the 
receptor complex [81]. One of these alterations has been shown to have a higher 
prevalence in a small subset of NIDDM patients [81]. It could be that as AGEs 
appear to have a role to play in exacerbating diabetic retinopathy, polymorphic 
alterations in the AGEs receptor(s) could predispose diabetic patients to advanced 
retinopathy, or moderate tolerance to poor glucose management [64, 73, 78, 83]. 
 
3.3 Other Retinal Vascular Diseases 
Idiopathic Macular Telangiectasia (MacTel) is a relatively rare disease (Beaver Dam 
Eye Study reported the disease prevalence is 0.1%, which although small still results 
in approximately 70,000 people in the US being affected [84] of the eye, first 
described in 1982. There are currently considered to be two variants of MacTel, 
aneurismal telangiectasia and perifoveal telangiectasia (figure 8). Most research has 
focused on the latter, as this is the most common form. Perifoveal MacTel occurs in 
two phases; the first being a non-proliferative stage in which there is loss of macular 
pigment and the retinal capillaries appear to dilate and leak. The second phase is an 
advanced stage where the capillaries proliferate into the foveal region and become 
tortuous displaying the characteristic telangiectasia phenotype. As the disease 
progresses further the vessels dive downwards through the retinal layers and make 
contact with the RPE. This contact appears to induce RPE proliferation up the vessel 
and causes vessel-RPE plaques to form. Foveal invasion leads to a progressive loss of 
central vision, which can eventually result in complete central blindness [85, 88]. 
Little is known about the causes of the disease, however recent studies have revealed 
a significant reduction in macular pigment in patients with MacTel [87, 88] 
suggesting that central loss of cone photoreceptors may be linked to increased 
oxidative stress. Furthermore, it was research into the basic cell biology of MacTel, 
undertaken as a part of the MacTel project [89] which led to the discoveries that 
paved the way for the work in this thesis. 
 
Retinal vein occlusion can be sub-divided into three types; central retinal vein 
occlusion (CRVO), hemiretinal vein occlusion (HRVO) and branch retinal vein 
occlusion (BRVO). The leading cause of retinal vein occlusion is thrombus formation 
 31 
thickening the neighbouring artery and therefore compressing the vein [90]. As with 
AMD, retinal occlusion is most common in people over 50yrs of age. Patients often 
have a history of atherosclerotic disease, hypertension and possibly diabetes. Vein 
occlusions are sometimes found in younger patients with a family history of vascular 
disease, or diseases where there is thickening of the blood making it more prone to 
forming a thrombus [90]. Most patients will report a sudden loss of vision, with 
CRVO patients found to also have iris neovascularisation upon clinical examination. 
Treatment is often laser ablation or surgical intervention to widen the vein and / or 
remove the thrombus. Tissue plasminogen activator (t-PA), a clot selective, 
recombinant fibrinolytic protein has shown some success in treatment of occlusion 
caused by thrombosis [90]. However targeted delivery of the protein is problematic 
with a chance of severe complications, which could prove fatal [90]. 
 
Figure 8: Fluorescein Angiogram Displaying Macular Telangiectasia. A) Arrow shows perifoveal 
leakage B) Arrow shows exudative scarring of the foveal region. Images taken from the vitreous-
retina-macula consultants of New York webpage resource http://www.vrmny.com/pe/ipt.html 
 
 
Coats’ disease (also known as exudative retinitis) is a rare eye disease, which usually 
affects males in the first decade of life. It is a developmental disease where the 
choroidal capillary bed fails to form properly so the vessels leak causing structural 
and functional break-down of the retinal barrier as well as macular odema, generation 
of lipid deposits within the tissue and retinal detachment [90-92]. The disease can be 
divided into five stages; 1) Telangiectasia only – if caught early this stage of the 
disease can sometimes be successfully treated with laser coagulation therapy to 
remove the excessive vessels. 2) Telangiectasia and exudate – this stage can be 
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further subdivided into 2a, where the fovea is unaffected by the leakage or 2b, where 
the fovea is affected. Visual impairment can sometimes be successfully treated with 
laser coagulation or cryotherapy depending on the extent of leakage. 3) Subretinal or 
retinal detachment – this stage can also be further subdivided into 3a, where the 
retinal detachment is incomplete or 3b, where there is total retinal detachment. This 
stage of the disease may require surgery to repair the detachment. 4) Total retinal 
detachment and glaucoma – by this stage of the disease there is a dramatic loss of 
vision and limited treatment options. There can be severe pain in the eye due to 
increased ocular pressure, when this occurs enucleation is recommended. 5) Total 
blindness – this is the final stage of Coats’ disease when the patient experiences total 
blindness. There is no treatment for the condition at this stage.  
 
The cause of Coats’ disease is unclear, it has been suggested that 
hypercholesterolaemia could contribute to adult Coats’ but there is little experimental 
evidence for this [89]. A link has been found between Coats’ and a somatic mutation 
in the Norrie disease protein (NDP), suggesting that a deficiency in the Norrin 
protein during development could lead to retinal vascular abnormalities [93]. Mice 
lacking Norrin appear to exhibit retinal disorganisation, and under development of 
the capillary bed supported a requirement for Norrin in the developing eye [93].  
 
Eales' disease is an idiopathic inflammatory venous occlusion, which commonly 
affects males aged 14-29. Symptoms of the disease include vitreous haemorrhage and 
vascular proliferation. The exact causes of Eales’ disease is not known, however, 
inflammation is commonly documented in the first stages of clinical presentation. 
Therefore suggesting a link between enhanced inflammation and the vascular disease 
progression [94]. 
 
Uveitis is an inflammatory disease of the uveal tract of the eye, made up of the iris, 
choroid and ciliary body. Any and all of these sections of the uvea can be affected 
thus giving rise to location specific types of uveitis. As overactive inflammation is 
the driving force behind the disease it is unsurprising that there is a high association 
between infection and uveitis. Anterior uveitis affects the iris and so can also be 
known as Iritis. It is the most common form of the disease accounting for 75% of 
patients and can occur suddenly, persisting for weeks even with treatment. It is also 
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found to be associated with autoimmune disorders such as rheumatoid arthritis. 
Intermediate uveitus, as the name suggests, affects the middle portion of the uveal 
tract and can disrupt the function of the muscles used to focus the lens. This form can 
also occur suddenly and persist for weeks or months even with treatment. Posterior 
uveitis affects the retina or choroid (or both) and can prove to be rapidly progressive, 
involving neovascularisation making it difficult to treat. Uveitis can be slow to 
respond to medication and threatens vision meaning it needs to be diagnosed and 
treated quickly. Antibiotics are used to fight the underlying infection and steroids can 
be prescribed to help with swelling [95]. 
 
4. Current Treatment for Retinal Vascular Diseases 
Current treatment options can offer some symptomatic relief to patients but as yet 
there is no complete cure for retinal vascular disease. Frequently in diseases, such as 
those described in the previous sections, the severity of vision loss is caused by 
uncontrolled retinal or choroidal vessel proliferation and / or leakage. This means that 
treatments which target blood vessel behaviour can be of value.  
 
Photodynamic therapy is an essentially destructive modality, but is one of the longest 
standing treatments for eye disease caused by abnormal vascular growth. This 
treatment utlises the photosensitivity of verteporfin. Normally verteporfin is stable 
but when it comes into contact with light it reacts with oxygen to become cytotoxic. 
By giving patients systemic injections of a drug that contains verteporfin the doctor 
can then wait for the drug to reach the abnormal retinal vessels, activate the drug with 
a laser and produce the cytotoxic reaction to kill the blood vessels [96]. The 
disadvantage of this treatment is that whilst it blocks or removes unwanted blood 
vessels, it doesn’t eliminate the signals responsible for vascular growth, so it may 
have to be used in conjunction with other treatments [96]. Another problem is that 
after injection the patient remains light sensitive for up to 48h and so will need to be 
advised about what levels of light they can tolerate. There can also be some 
temporary visual disturbance or in rarer cases patients can experience a dramatic 
reduction in their vision for longer periods of time [96, 97].  
 
Angiogenic factors make attractive therapeutic targets for retinal vascular disease, as 
well as other vessel pathologies. In some circumstances, such as stroke where limited 
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blood supply is a problem, promoting angiogenesis could be beneficial. In other cases 
such as in ophthalmic disease or cancer, where it has been calculated that a tumour 
cannot grow beyond 2mm3 if it fails to establish a blood supply, inhibiting 
angiogenesis could prevent disease progression [23].  
 
As VEGF-A has been shown to increase endothelial migration and proliferation it is 
not surprising that deregulated expression and activity is often seen in disease [16, 
98]. As a result some of the most effective current treatments for AMD work by 
inhibiting the effects of VEGF, either by blocking the VEGF receptor (VEGFR2) or 
by sequestering free VEGF[57]. The main VEGF inhibitor commonly used for the 
treatment of AMD is Ranibizumab (Lucentis). Lucentis was developed on a Fab 
fragment of a full length humanized monoclonal antibody, Bevacizumab (Avastin). 
Avastin was originally developed for the treatment of bowel cancer, but Lucentis has 
a much higher affinity for VEGF [98]. In 2006 the Food and Drug Administration 
(FDA) in the USA, and in 2008 the National Institute of Health and Clinical 
Excellence (NICE) in the UK approved Lucentis for use in the treatment of 
neovascular AMD. Patients given monthly intravitreal injections of Lucentis were 
compared to patients who received a sham injection. The results showed that 95% of 
the Lucentis patients reported stabilisation of their symptoms and that 40% 
experienced an improvement in their vision, as assessed by a gain of 15 or more 
readable letters in their central acuity [98, 102].  
 
Because Avastin was originally marketed as a treatment for metastatic colorectal 
cancer it has not officially been approved as a treatment option for retinal vascular 
diseases, however it has a much longer half life than Lucentis (taking 100 times 
longer to clear from the circulation) meaning patients do not require as many 
injections, and it is substantially cheaper. It is estimated that there are approximately 
25,000 new cases of AMD every year in the UK and that if all patients received 
Lucentis it would cost the National Health Service £300 million, whereas Avastin 
treatment would reduce this bill by £292 million [101]. A potential disadvantage of 
using Avastin instead of Lucentis is that whereas Lucentis is retained in the eye upon 
intraocular injection, Avastin may enter the systemic circulation, in fact it has been 
detected in blood of treated rabbits three weeks post-injection [102]. This could 
potentially lead to adverse side effects by inhibiting VEGF signalling elsewhere in 
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the body. Other general drawbacks to treating eye disease with VEGF inhibitors such 
as Avastin and Lucentis are that VEGF is also a key survival factor for neurons and 
Muller cells within the retina meaning its inhibition could still threaten vision [100]. 
Also, VEGF is  often up-regulated in the later stages of disease, so by the time the 
drugs are prescribed it is not unusual for significant vision loss to have already 
occurred. Secondly, VEGF inhibitors may slow further disease but they cannot repair 
existing damage, and lastly the method of drug delivery is monthly intravitreal 
injection which is unappealing to patients and there is a small (<1%) risk of causing 
intraocular inflammation, retinal detachment or retinal tearing [102]. Despite the 
wide use of Lucentis it is reported that only 50% of patients respond to the drug, and 
as it is only used for treatment of neovascular ‘wet’ AMD, which accounts for only 
10% of AMD cases, it is clear that although useful, Lucentis is not going to be ‘cure-
all’ for retinal vascular disease [37, 57, 96].  
 
Alongside these VEGF antibodies pharmaceutical companies have also developed 
‘VEGF traps’ such as Aflibercept, which is a recombinant fusion protein of the 
VEGF receptor and the Fc domain of IgG1 [101]. Aflibercept differs from Avastin 
and Lucentis because it is not an antibody against VEGF, instead it utlises the VEGF 
receptor structure to capture the growth factor and prevent it from initiating its 
signalling effects [101]. 
 
VEGF is not the only growth factor that can promote vascular changes, and since 
patients receiving treatments such as Avastin frequently develop resistance to this 
therapy, other therapeutic modalities are required [99]. Thus, new therapeutic 
antibodies are being assessed in clinical trials, including a promising PlGF blocker, 
as well as small molecule inhibitors such as Sunitinib and Sorafenib (figure 9) [102, 
104]. 
 
Sunitinib is a multi-tyrosine kinase inhibitor that has been shown to target all of the 
VEGFRs as well as the platelet-derived growth factor receptors (PDGF-Rs), which 
have been shown to promote angiogenesis [105]. Sorafenib (also known as Nexavar) 
is another multi-tyrosine kinase inhibitor also able to inhibit VEGFR and PDGF-Rs 
as well as the Raf serine threonine kinase, thereby preventing ERK activation and 
subsequent endothelial cell proliferation [[106, 107]. Both of these drugs have been 
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commissioned for use in cancer treatment. Sunitinib is considered the first drug 
choice for patients with advanced metastatic renal cell carcinoma, and Sorafenib is 
often used for treating hepatocellular carcinoma [101, 107]. The obvious 
disadvantage to using non-specific inhibitors is that they can have off target effects, 
thus causing adverse side effects in non-disease affected tissues [95].  
 
 
Figure 9: Anti-angiogenic Drug Targets. Drawing to show where some of the current therapeutics 
target the angiogenic pathway. Examples A) Lucentis and Avastin B) Aflibercept C) Sunitinib and 
Sorafenib. [102] 
 
 
One of the more promising targets for anti-angiogenic therapeutics is PlGF. PlGF 
belongs to the same cysteine knot superfamily of growth factors as VEGF and also 
shows affinity for the VEGF receptors. However, unlike VEGF-A, PlGF does not 
signal through VEGFR2, instead it has been found to initiate its effects through 
VEGFR1, Np-1 and Np-2. PlGF has been reported to enhance VEGF-A signalling in 
several ways – 1) Displacing VEGF-A from VEGFR1, thus making VEGF-A free 
and able to bind VEGFR2 to induce signalling activity [103]. 2) Binding of PlGF to 
VEGFR1 promotes cross-talk between VEGFR1+2 amplifying VEGFR2 signalling  
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[108, 109]. 3) PlGF signalling through VEGFR1 activates transcription of VEGF-A 
as well as other growth factors FGF2 and PDGF [107]. In vivo research has shown 
that PlGF is not required for vascular development but that it plays a role in 
pathogenic angiogenesis, inflammation and vascular leakage. Treatment with an anti-
PlGF antibody has been shown to inhibit choroidal neovascularisation (CNV) in a 
mouse model of retinal vascular disease and promote regression of pre-existing 
tumour vasculature [102, 110]. PlGF is therefore a very attractive drug target for 
vascular disease due to it being involved only in pathogenic vasculogenesis. This 
means that targeting PlGF could permit treatment of the disease vasculature without 
affecting healthy blood vessels [102, 109].  
 
Overall the available treatments for ocular vascular disease are limited and of 
variable efficacy. They can offer symptomatic relief but do not target the cause of 
disease and as they often target disease in its later stages they cannot repair damage 
already caused. In order to treat eye disease successfully a better understanding is 
needed of the driving forces behind abnormal vessel behaviour, and the molecular 
mechanisms that lead to increased VEGF production. In addition, greater insight into 
the earlier stages of disease and identification of novel markers for disease 
progression may permit diagnosis at earlier stages, and lead us to alternate drug 
targets suitable for earlier intervention.  
 
5. A Genetic Screen to Identify Novel Drug Targets 
To obtain new insight into the genetic changes responsible for pathogenic 
neovascularisation our lab carried out a microarray analysis of the genes expressed in 
isolated retinal vessels from three mouse mutants displaying varying degrees of 
vascular abnormality.  
 
The mouse models chosen were the very-low density lipoprotein receptor knock out 
(VLDLR-/-), the retinal dystrophic-1 (RD1) and the Grhl3CT/J Curlytail mouse (CT). 
Neuroretinal tissue was dissected from the eyes of each mouse at an age at which 
vessel disease was established (16 weeks for VLDLR-/- and RD1, 12 weeks for CT). 
Vessel fragments were affinity purified from which ribonucleic acid (RNA) was then 
isolated, and global gene expression was compared to age-matched C57B6 wild-type 
mice.  Bioinformatic analysis of the microarray data, using FDR and a P value of 
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<0.01, to define significance, led to the identification of sixty-two genes that 
commonly changed in all three mouse models when compared to controls. One of the 
most substantially up-regulated genes was LBP, which encodes the 
Lipopolysaccharide Binding Protein.  
 
6. Lipopolysaccharide Binding Protein 
6.1 Overview  
The Lipopolysaccharide Binding Protein (LBP) is a 60kDa acute phase response 
glycoprotein that is primarily expressed and secreted by hepatocytes and 
macrophages. It belongs to the same protein family as bactericidal permeability-
increasing protein (BPI), plasma cholesteryl ester transfer protein (CETP), and 
phospholipid transfer protein (PLTP), all members of which share a high degree of 
structural similarity and certain related functions [111, 112]. The LBP and BPI genes 
are both located on chromosome 20, and although they exhibit some marked 
differences in their bioactivity they have substantial sequence homology. Protein 
crystallography analysis of BPI has shown the protein to have a two domain ‘hinge-
like’ structure. This structure is expected to be similar for LBP due to the fact that 
they share 45% amino acid sequence identity [113-115].  
 
6.2 Immune Role 
LBP functions, as its name suggests, to bind lipopolysaccharide (LPS), a cell wall 
component of gram-negative bacteria such as E. coli. The N-terminal domains of 
LBP and BPI appear to be responsible for the ability of the proteins to recognise and 
bind to LPS. However, whilst the antibacterial function of BPI is also dependent on a 
portion of the N-terminus [114]. LBP requires its C-terminus to either clear the 
endotoxin through transferring it to high density lipoproteins (HDL) or to elicit 
inflammatory signalling by presenting the endotoxin to soluble CD14 (sCD14) or 
membrane bound CD14  (mCD14) to activate cell signalling cascades (figure 10) 
[115]. LBP-LPS-CD14 activates pattern recognition receptors such as the toll like 
receptors (TLR), among which TLR4 is particularly important, which in turn leads to 
expression of key inflammatory agents such as TNFα and interleukins 1 and 6 (IL1, 
IL6) [116-118]. 
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TLR4 was the first pattern recognition receptor identified, and following elucidation 
of its key role in mediating LPS-induced septic shock in the late 1990s it has been the 
focus of much research. As a result it is now one of the best characterised members 
of the TLR family [119]. Presentation of endotoxins such as LPS to TLR4 have been 
found to induce tyrosine phosphorylation of its Toll-IL-1 resistance (TIR) domain, 
which is then thought to recruit intracellular adaptor molecules and enable signalling 
cascades primarily through the NF-kß pathway [120-121]. TLR4 is currently the only 
known member of the TLR family which can recruit and activate two alternate TIR 
recognising adaptor proteins, namely MyD88 and the toll-like receptor adaptor 
molecule 1 (TICAM1 or TRAF). By signalling through these two adaptors TLR4 is 
able to mediate both an early phase of NF-kß transcription (through MyD88) as well 
as a later phase (through TRAF) [116-122]. 
 
 
Figure 10: A Schematic Showing the LBP + LPS Inflammatory Signalling Cascade in an 
Endothelial Cell. LBP binds to LPS and initiates docking the endotoxin at the cell surface either via 
membrane surface antigen CD14 or circulating CD14. This then induces TLR4 and MD-2 (a 25kDa 
protein required for TLR4 membrane localisation) heterodimers and activates receptor auto-
phosphorylation. MYD-88 is then recruited and intracellular signalling through IRAK-1, TRAF 6, 
TAK1 and IKKαßγ, release of p65 and p50 and their nuclear localisation for NF-kß transcription 
activity. Image taken from MedScape news http://www.medscape.com/viewarticle/706510_4 
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Mammals express five NF-kß family members related by their Rel homology 
domains (RHD); p50, p52, p65 (also known as RelA), c-Rel and RelB. The RHDs 
enable these transcriptional elements to form any combination of homo and 
heterodimers which can then recognise kß binding sites present in specific gene 
promoters to modulate gene transcription. In the case of RelA, c-Rel and RelB, gene 
expression is activated, whereas p50 and p52 will only activate transcription as a 
heterodimer with RelA, c-Rel or RelB [122-124].  In contrast, when these molecules 
form homo or heterodimers with one another they inhibit gene transcription. All 
members of the NF-kß family are constitutively expressed and maintained in an 
inhibited sequestered form in the cell cytoplasm through their interactions with 
inhibitory Ikß proteins. There are currently seven known IkB inhibitory proteins; 
ikßα, Ikßb, Bcl-3, Ikße, Ikßg and the precursor proteins for p50 and p52, p100 and 
p105 [125]. 
 
There are two types of signalling that have been found to induce NF-kß activity, 
these being the canonical pathway which involves a ligand being presented to a 
membrane receptor (such as LPS-TLR4) leading to intracellular signalling through 
the recognition of phosphorylated sites, and the non-canonical pathway which is only 
generally observed during the development of lymphoid tissue. These two pathways 
are separated by the NF-kß elements through which they act, whereby the canonical 
pathway leads to the formation of dimers of RelA, c-Rel, RelB and p50, whilst the 
non-canonical pathway is reponsible for p52/RelB acitivity [122-124]. NF-kß activity 
has been shown to effect genes responsible for inflammatory responses, cell survival, 
cell differentiation and cell proliferation [122-125]. In view of these pleiotropic 
activities, it is unsurprising that poorly controlled NF-kß signalling is linked to 
disease, indeed up regulation of NF-kß activity has been linked to cancer, 
autoimmune disorders and chronic inflammatory conditions [124-127].  
 
6.3 Immunity and Angiogenesis 
Cancer progression is dependent on tumour cells receiving an adequate nutrient 
supply, which is achieved through successful angiogenesis. Angiogenic potential now 
appears to be determined by the tumour ‘microenvironment’, meaning the 
neighbouring cells and the factors they secrete [124]. Research has shown that these 
microenvironments are packed with immune cells and that prognosis for the patient 
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appears to be at least partly dependent on the balance between anti-tumour and pro-
tumour immune responses [129].  
 
T cells have been found to exert pro and anti-tumour effects depending on their 
cellular status. High levels of CD4+ helper type-1 T cells (Th-1) in the tumour 
microenvironment appear to correlate with a better prognosis in colorectal cancer, 
whereas CD8+ and CD4+ helper T cells, activated by IFNγ appear to promote 
metastasis. T cells have also been found to educate tumour associated macrophages 
(TAMs), activating them to secrete proliferative factors, making them pro-angiogenic 
in breast cancer [130, 131]. When macrophages were first discovered they were 
considered to function only as scavenger cells. However, investigators soon noticed 
that macrophages secrete an array of functionally important proteins, and by 1976 the 
scavenger had emerged as a major player in angiogenesis [132-134]. TAMs are now 
known to be the principle source of cytokines and angiogenic factors in tumour 
development [132-134]. The macrophages effect appears to depend on its activation 
ligand – e.g. those that have been activated by a microbial ligand or IFNγ and 
expresses high levels of proinflammatory cytokines (e.g. TNFα, IL-1 and IL-6), have 
been linked to anti-tumour responses whereas macrophages that have been activated 
by IL-4, IL-10 or IL-13 and express high levels of anti-inflammatory cytokines (e.g. 
IL-10, arginase, scavenger receptor A) have been demonstrated as having tumour 
promoting abilities [49, 133]. It has been suggested that tumour inhibition or 
progression is solely dependent on the chemokine profile within the 
microenvironment and is not really reliant on the immune cell type producing the 
signals. IL-6, IL-17 and IL-23 have been shown to be pro-tumourigenic whilst IL-12, 
TRAIL and IFNγ are generally anti-tumourigenic [134, 135].  
 
As previously discussed, LBP is secreted by macrophages and has a well 
characterised role in inducing inflammatory signalling through TLR4 and NF-kß 
activation [124]. However, in 2003 LBP was also suggested to be a key player in 
what is now being termed the ‘angiogenic switch’. Macrophages when stimulated 
with LBP-LPS were reported to increase their expression of inflammatory cytokines 
through activation of TLRs, however it was shown that if the macrophage was co-
stimulated with an adenosine A2a receptor (A2aR) agonist the signalling cascade 
appeared to shift from inflammatory to anti-inflammatory, with an accompanying 
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increase in VEGF expression [136, 137]. This suggests that LBP could function in 
two different roles depending on the cell environment upon activation.  
 
Macrophages, as previously mentioned, are increasingly associated with angiogenesis 
through the factors they secrete. LBP is secreted by macrophages but the possibility 
that LBP may have angiogenic activity has not been investigated. However, the 
identification of the angiogenic switch provides a rationale for LBP acting as a pro-
angiogenic factor in certain conditions. Exactly how a macrophage is activated to 
produce certain cell surface antigens or secrete certain proteins is not yet fully 
understood, but it is thought that for a macrophage to become pro-angiogenic it 
requires more then just exposure to an infectious agent such as LPS [49]. This 
supports a model of angiogenesis being a multifactorial process that requires specific 
signal initiators alongside unique environmental cues.   
 
6.4 LBP in the Retina and Signalling  
Work from our laboratory that led up to this project identified LBP as a significantly 
up regulated gene in three mouse mutants of retinal vascular disease. The microarray 
analysis was performed on isolated retinal vessels, indicating that LBP is expressed 
by cells of the retinal vasculature, most likely a mixture of endothelial cells, pericytes 
and possibly Müller cells. As the mice used in this analysis were notionally free of 
LPS this suggests that LBP may have some other unknown function beyond its well 
characterised immunological role.   
 
As discussed previously (see section 3.1) the protein with the highest homology to 
LBP is BPI [114]. BPI was once considered to function solely in an immune role to 
clear LPS, however in 2006 it was found to induce pericyte and RPE growth whilst 
suppressing VEGF-induced endothelial growth factor [138] and then in 2007 a paper 
by Geraldes et al, reported that BPI was able to signal through the Glypican 4 
(GPC4) receptor to activate two serine and threonine kinases, namely extracellular 
signal regulated kinase (ERK1/2, also known as mitogen activated serine/threonine 
protein kinase, MAPK) and Akt (also known as protein kinase B, PKB) in RPE and 
pericytes [139].  
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It is intriguing that BPI, a structurally similar protein to LBP has been found to 
induce these kinases as both of these kinase families are implicated in angiogenesis 
[140].  
 
There are three isoforms of Akt in humans, differing in their physiological functions 
and tissue expression profiles – Akt1 is a regulator of cell survival and is abundantly 
expressed in the heart, brain and liver. Akt2 is required for glucose metabolism and 
has been found to increase glucose uptake through incorporation of GLUT4 receptor 
into the plasma membrane, it is expressed in skeletal muscle. The function of Akt3 is 
less clear but it is expressed highly in the brain, and mice lacking Akt3 have been 
reported to have a decreased brain size [141]. Under normal cell conditions, Akt is 
found in the cytoplasm in a non-phosphorylated state. However, stimulation of 
certain cell surface receptors may induce activation of phosphoinositide 3-kinase 
(PI3K), which in turn generates phosphatidylinositol (3,4)-bisphosphate (PIP2) in the 
cell membrane. This creates a binding site for Akt, thus anchoring it at the plasma 
membrane where it may be phosphorylated by two kinases, 3-phosphoinositide-
dependent protein kinase 1+2 (PDK1+2) on threonine 308 and serine 473 [141]. This 
phosphorylation activates Akt enabling it to phosphorylate its downstream targets 
(e.g. Bad), leading to gene transcription promoting cell survival, proliferation and 
migration [141, 142]. Interestingly, mice lacking Akt1 have been found to have an 
inhibition in physiological angiogenesis but an enhancement in pathological vessel 
growth [142]. 
 
ERK1/2 are well characterised kinases known to be important regulators of a range of 
cellular processes including proliferation, survival and differentiation, with their 
dysregulation being reported in a wide variety of cancers [143]. There are believed to 
be over 160 ERK1/2 substrates all sharing the same modulation motif, X-Pro-Xaan-
Ser/Thr-Pro-X. The best characterised signalling cascade featuring ERK is the 
Raf/MAPK pathway. Ligand interaction with a cell surface receptor induces Raf 
(MAP3K) activation, which then phosphorylates and activates MEK1/2 (MAP2K), 
which then phosphorylates and activates ERK1/2 (MAPK). Active ERK1/2 can then 
phosphorylate its downstream targets, which include a variety of transcription factors 
such as CREB, c-Fos, c-Jun and STAT, which in turn leads to modification of 
cellular behaviour [143, 144].  
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7. Hypothesis and Aims 
 
These observations form the background to the work undertaken in this thesis. The 
aim of this project was to test the hypothesis that LBP has an as yet uncharacterized 
role in angiogenesis. 
 
• Characterisation of LBP and growth factor expression in the VLDLR-/- mouse 
through the use of quantitative PCR analysis, retina flat mounting and tissue staining. 
 
• Investigation of the angiogenic potential of LBP, both alone and in conjunction with 
other established growth factors such as VEGF through the use of in vitro and ex vivo 
growth assays and the oxygen induced retinopathy (OIR) mouse protocol. 
 
• Investigation of LBP’s ability to induce cell signalling independently of LPS in a 
range of available cell culture lines using molecular chemistry techniques such as 
Western blotting, immunocytochemistry, co-immunoprecipitation and genetic siRNA 
knock down. 
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Materials and Methods 
 
 
1. Cell Culture 
1.1 Cell Lines 
Human Umbilical Vein Endothelial Cells (HUVEC), isolated from normal human 
umbilical veins were ordered from Lonza as a cryopreserved stock of ~7 x 105 cells in 
passage one. HUVEC were seeded onto 1% bovine skin gelatin (Sigma G9382) coated 
plastic tissue culture flasks and maintained in EGM2 (Lonza Clonetics CC-3162 
containing growth supplements Hydrocortisone, hFGF-B, VEGF, R3-IGF-1, Ascorbic 
Acid, Heparin, FBS, hEGF, GA-1000) medium. Cultures were grown to confluency at 
37oC in 5% CO2 with media replaced every 2-3 days.  
 
The GPNT 24.6 cell line (Regina et al 1999) is a re-immortalised subclone of the 
Lewis rat brain endothelial cell line GP8 (Greenwood et al 1996). The cells were 
originally derived from primary cultures and immortalised by expression of the SV40 
large T antigen. GPNT cells were seeded onto a 0.005% calf skin collagen I (Sigma 
C8919 containing 0.1M acetic acid) coated plastic tissue culture flask and maintained 
in a 1:1 mix of Ham’s F-10 medium (containing L-glutamine) and a minimal essential 
medium alpha (MEMa) with Glutamax, supplemented with 10% FCS, 100U/ml 
penicillin and 100µg/ml streptomycin. Cultures were grown to confluency at 37oC in 
5% CO2 with media replaced every 2-3 days. 
 
The rat brain endothelial (RBE4) cell line is a well-characterised in vitro model for the 
blood brain barrier (BBB). RBE4 cells were seeded onto a 0.005% calf skin collagen I 
(Sigma C8919 containing 0.1M acetic acid) coated plastic tissue culture flask and 
maintained in a 1:1 mix of Ham’s F-10 medium (containing L-glutamine) and minimal 
essential medium alpha (MEMa) with Glutamax, supplemented with 10% FCS, 
100U/ml penicillin and 100µg/ml streptomycin. Cultures were grown to confluency at 
37oC in 5% CO2 with media replaced every 2-3 days. 
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The MIO-M1 cell line was isolated from spontaneous immortalised Müller cells 
derived from eyes obtained from Moorfields Hospital Eye Bank [138]. MIO-M1 were 
seeded directly onto tissue culture plastics and maintained in DMEM (containing L-
glutamine and 4.5g/l glucose, Lonza) supplemented with 10% FCS, 100U/ml 
penicillin and 100µg/ml streptomycin. Cultures were grown to confluency at 37oC in 
5% CO2 with media replaced every 2-3 days. 
 
1.2 Thawing Cells 
Cryoamps of cell lines were defrosted rapidly in a 37oC waterbath, appropriate cell 
line specific media were then added and the cells pipetted into a universal tube. The 
cells were then placed into a centrifuge and spun at 1100 rpm for 3 min. After 
pelleting, the supernatant was removed and the cells resuspended in their specific 
media before being transferred to a tissue culture flask containing ample cell media. 
Media were replaced after 24 h. 
 
1.3 Collagen Coating 
For GPNT and RBE4 cells the tissue culture flasks and dishes were coated with a 1:20 
dilution of type I collagen (Sigma C8919 0.1% calf skin collagen containing 0.1M 
acetic acid) in HBSS (-Mg2+ and Ca2+) overnight at 37oC in 5% CO2. The following 
day the collagen I was aspirated and the flask / dish washed twice in HBSS (-Mg2+ and 
Ca2+) before cells were plated. 
 
1.4 Splitting / Plating Cells 
Cells were split routinely once confluent or when experiments required plating. The 
flask of cells was washed once in PBS (-Mg2+ and Ca2+) before adding an appropriate 
volume (example 3ml for a T75 flask) of 1x trypsin and incubated at 37oC until the a 
single cell suspension had formed. Media containing serum was then added to the 
flask to halt further proteolysis and the suspension transferred to a universal tube and 
spun at 1100 rpm for 3 min to pellet the cells. The supernatant was then aspirated and 
the cell pellet resuspended in the desired volume of medium. The cells were then 
plated at the desired density for experiments or re-seeded for continuing cell culture 
flasks. GPNT and RBE4 were seeded at a maximum dilution of 1:10 whilst MIO-MI 
and HUVEC were seeded at a maximum dilution of 1:6. 
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1.5 Cryopreserving Cells 
A confluent flask of cells was trypsinised as described. The cell pellet was then 
resuspended in 1ml specific cell line media supplemented with 10% dimethyl 
sulfoxide (DMSO) and frozen in cryotubes. The cryotubes were cooled on ice for 10 
min, frozen at -70oC overnight and then placed into liquid nitrogen for long term 
storage.  
 
2. Imaging 
2.1 p65 Staining 
MIO-MI cells were grown to confluency in 35mm2 MatTek culture dishes before 
being treated with 10ng/ml recombinant human lipopolysaccharide binding protein, 
(LBP) (R&D Systems 870-LP lypophilized from 0.2µm filtered solution containing 
20mM Tris, 100mM NaCl, 0.05mM EDTA, pH 8.0 containing 50µg bovine serum 
albumin per 1µg of cytokine) for 15 min +/- 50µg Lipopolysaccharide (LPS) (Sigma 
L8274 from E.Coli sterotype).  The cells were then extensively washed with ice cold 
PBS and fixed by addition of 3.7% formaldehyde for 15 min followed by gentle 
washing with PBS. Cells were then permeabilised by addition of ice cold acetone to 
residual PBS for 30 s followed by rapid dilution in 0.1% BSA/PBS. The dishes were 
then blocked in 0.5% BSA/PBS for 15 min before a 90 min incubation in rabbit anti-
p65 (Santa Cruz C-20, 0.2µg/ml) and DAPI bisbenzimide (1µg/ml). Cells were then 
washed extensively in PBS and incubated with fluorophore-conjugated anti-isotype 
specific pre-adsorbed secondary (Ig-FITC) antibody diluted in blocking solution for 45 
min in the dark. Dishes were then washed extensively with PBS and mounted under 
Vectashield with glass coverslips.  
 
2.1.1 Cell Imaging 
To generate images, samples were observed for fluorescence using an inverted 
epifluorescent Leica microscope. DAPI images were taken using a 364nm wavelength 
light and FITC images with a RFP2 filter (594nm). Samples were viewed at 20x 
magnification and the exposure and gain settings were fixed across all treatment 
conditions to facilitate subsequent comparative analysis. Images were then saved as 2-
channel 24-bit tiff files or as individual 8-bit grey tiff files. 
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2.2 Flat Mounts 
2.2.1 Tissue Preparation 
Whole mouse eyes were placed into 2x PBS / 2% PFA for 2 min. An incision around 
the eye was then made, below the aura striata and the cornea and lens disregarded. The 
neuroretina was then peeled away from the RPE/choroid and placed into fresh 2x PBS. 
Dissection scissors were then used to make cuts in four corners of the tissue and PBS 
aspirated to enable the neuroretina to lie flat. Ice-cold methanol (100%) was then 
added dropwise onto the tissue, turning it white and causing it to float. The sample 
was then placed at -20oC for 20 min. The sample was then returned to room 
temperature and the methanol diluted out with PBS. The tissue was then transferred to 
a 96-well plate in fresh PBS, incubated at room temperature for a further 30 min and 
then placed into a blocking buffer containing 3% Triton X-100, 0.5% Tween-20, 1% 
BSA for another 30 min. The tissue was then incubated at room temperature overnight 
in 0.5mg/ml rat anti-mouse collagen IV antibody (BD Pharmingen) diluted 1:200 in 
blocking buffer. The following morning the primary antibody solution was removed 
and the tissue washed in fresh blocking buffer 3 x 10 min on a plate shaker.  The 
sample was then incubated in AlexaFlour 594 (Invitrogen rabbit anti-rat IgG 2mg/ml) 
secondary antibody and isolectinB4 (Vector simplicifolia lectin 1 FL-1201) 
conjugated antibody, diluted 1/200 in blocking buffer for 1 h at room temperature. The 
wash step was repeated followed by the sample being mounted onto a microscope 
slide via Mowiol immersion. 
 
2.2.2 Tissue Imaging 
To generate images samples were observed for fluorescence using an inverted 
epifluorescent Leica microscope. Collagen IV-FITC was visualised with a RFP2 filter 
(594nm) at a 40x magnification focus adjustment used to observe the deeper plexus 
layer of the retinal vessels, with the exposure and gain settings being fixed across all 
tissue samples to permit comparative analysis. Images were then saved as 
monochannel 24-bit tiff files.  
 
2.3 Tissue Sections 
The eyes from 16-week-old wild type and VLDLR-/- mice were dissected, the lens 
removed and the ‘eye cup’ fixed in PFA and embedded in OCT. The eyes were then 
section sliced and mounted onto glass coverslips to be stored at -80oC until required 
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for staining. When required the slide was removed from cold storage, residual OCT 
washed off with PBS before 3% H2O2 (in methanol) was added dropwise and left for 
30_m. The slides were then washed briefly in PBS before being transferred to a 
humidified chamber and blocked in 100% goat serum at RT for 1 h. The LBP antibody 
(Santa Cruz rabbit polyclonal) was then diluted 1:200 in 100% goat serum and 
incubated on the slides in the chamber at RT for 2 h. The slides were then washed 6 
times in PBS. Secondary anti-rabbit goat antibody (Vector Labs, ABC Kit) was then 
applied at RT for 1 h. Slides were washed 4 times in PBS and placed into final 
solution at RT for 30 m. They were then washed 3 times in PBS before 
Diaminobenzidine (DAB) (Sigma) added, with the slide being left at RT to develop 
(approx 20 m) before being washed thoroughly in H2O and mounted in glycerol for 
imaging using a light microscope. 
 
 
3. Molecular Biology 
3.1 RNA Isolation 
3.1.1 RNA Isolation from Cell Lines 
The RNeasy Mini Kit 250 (Qiagen) was used for the isolation of RNA from confluent 
cells.  The cells were washed once with D-PBS before being solubilised in lysis buffer 
RLT with β-mercaptoethanol (10µl/1ml of RLT) and then scraped. The homogenized 
lysate was directly added to the QIA shredder (Qiagen) and subjected to centrifugation 
for 2 min at room temperature at 50,000 x g. One volume of ethanol was added, mixed 
well and the sample was added to an RNeasy spin column. Centrifugation was carried 
out for 15 s and flowthrough was discarded. RNase-free Dnase set (Qiagen) was used 
to digest DNA as follows. RWI buffer (350µl) was added to the RNeasy spin column 
and spun for 15 s. DNase I stock solution (10µl) was added to 70µl buffer RDD, then 
added to the RNeasy spin column and left at room temperature for 15 min. A further 
350µl of buffer RWI was added and the flowthrough discarded. Once the sample was 
DNase treated 500µl of buffer RPE was added and centrifuged for 15 s, followed by a 
further addition of 500µl buffer RPE. Centrifugation for 2 min at 50,000 x g followed 
with a further 1 min to ensure complete elimination of buffer RPE and the 
contaminating ethanol therein. RNA elution then occurred with the addition of 30-50µl 
of RNase free water and the concentration of RNA was measured using a Thermo 
Scientific Nano-drop machine.   
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3.1.2 RNA Isolation from Animal Tissue 
3.1.2.1 RNA isolation from Neuroretina  
The neuroretina was dissected from the mouse eye (see dissection description in 2.2.1 
tissue preparation) and placed into 1ml Tri Reagent (Sigma T9424) and homogenised 
using a 23 & 26G needle. 200ul 1M Chloroform was added and the samples spun 12 x 
103 rpm in a centrifuge at 4oC for 10 min. The top aqueous layer was then carefully 
removed into a clean RNAse free Eppendorf tube and 500µl 1M isopropanol added to 
precipitate the genomic material. Sample tubes were then inverted for 15 s and 
samples left at RT for 15 min before being placed back into the centrifuge to repeat the 
spin as before. The isopropanol pellet is glassy so can be hard to observe, to overcome 
this problem glycogen can be added to visualise the pellet. The isopropanol 
supernatant was then decanted off and the tube blotted on RNAse zapped tissue. The 
pellet was then washed in 70% ethanol and again decanted and blotted as before. The 
pellet was then left to air dry for 30 seconds before being resuspended in 100µl 
RNAse free water and heat-treated at 50-60oC to linearise the genomic strands. The 
sample is then passed through the QIAGEN RNAeasy clean up protocol as described. 
 
3.1.2.2 RNA Isolation from Retinal Pigment Epithelium (RPE) and Choroid 
Once the neuroretina had been dissected out of the eye sample, the remaining ‘eye 
cup’ was placed into 1ml Tri Reagent (Sigma T9424) and placed on an Eppendorf 
roller at 4oC for 2 h. The tissue was then vortexed in the Tri Reagent to dissociate the 
RPE and the RNA isolation protocol carried out as for neuroretina. 
 
3.1.2.3 RNA Isolation from Isolated Retinal Vessels 
The neuroretina was dissected (see dissection description in 2.2.1 tissue preparation) 
and the tissue placed into 1ml collagenase/dispase digestion mix supplemented with 
10µl RNAse free DNAseI (Ambion 20U/µl) in an RNAse free Eppendorf tube. 
Samples were then incubted at 37oC for 1 h with pipetting up and down every 15 min. 
Samples centrifuged at 1400rpm for 5 min and the supernatant discarded. The pellet 
was resuspended in 1ml RNAse free PBS + 0.5% BSA + rat anti-mouse PECAM (BD 
Pharmingen) and placed on a rotator for 10 min. The sample was then spun again as 
before. Using a magnetic Eppendorf rack the anti-rat magnetic beads (Dynal BioTech 
Dynabeads anti-rat IgG, 4 x 108 beads/ml) were then washed 3 times in PBS and this 
bead mix was used to resuspend the tissue pellet. Sample and bead mix were then 
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placed back onto the rotator for 20 min, then back into the magnetic rack, whereupon 
the supernatant was removed and centrifuged at 1800rpm for 8 min, with pellet being 
resuspended in 1ml Tri reagent to use as a vessel-depleted sample. The magnetic beads 
were bound to the retinal vessels so these were placed in 1ml Tri reagent to generate a 
vessel-enriched sample. RNA was then isolated as described earlier for neuroretina 
and RPE. 
 
3.2 Protein Isolation 
3.2.1 Protein Isolation from Cell Culture 
Cells were plated on 35mm2 dishes to confluency and treated with desired treatments 
for desired time points. Cells were then washed in PBS before being lysed in 150µl of 
lysis buffer (125mM Tris pH 6.8, 4% SDS, 17.5% Glycerol, 5mg/ml bromophenol 
blue, 50mM DTT) and a cell scrapper used to dissociate cells. Samples were then 
pipetted into Eppendorf tubes and heat treated at 95oC for 5 min. 
 
3.2.2 Protein Isolation from Animal Tissue 
3.2.2.1 Protein Isolation from Neuroretina 
Neuroretinas were dissected as normal and placed in 250µl of lysis buffer before being 
placed on a rotator at 4oC for 30 min with pipetting up and down at 15 min to break up 
the tissue. The sample was then pulled through a 23 and 26 gauge needle and placed 
back onto the rotator for 10 min. After being spun at max speed (>13000rpm) 4oC for 
10 min the supernatant was removed and stored at -20oC whilst the pellet was 
resuspended in 250µl of fresh lysis buffer and also stored at -20oC.  
 
3.2.2.2 Protein Isolation from RPE and Choroid 
RPE and choroid were isolated from mouse eyes as describe earlier, and the entire ‘eye 
cup’ was placed in 200µl lysis buffer. The sample was vortexed briefly before being 
placed on ice for 10 min, and then vortexed again and observed to see if the lysate had 
become a mirky brown (due to release of pigment). If the colour did not change the 
sample was placed back on ice and inspected again at 10 min intervals. The tissue was 
then spun at max speed (>13000rpm) 4oC for 10 min and the supernatant removed and 
stored at -20oC. 
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3.3 Gel Electrophoresis 
3.3.1 Agarose RNA and DNA Gels 
For RNA and DNA analysis, 1-2% agarose (supplemented with 1µg/µl EtBr to 
visualise sample) gels were used. For a 200ml gel approximately 25ng DNA was 
loaded, supplemented with bromophenol blue loading dye, the gel was run at 70 V for 
1 h before being viewed under UV light. Bands were measured against a 1kb DNA 
ladder (Invitrogen).  
 
3.3.2 Protein Analysis 
3.3.2.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
A stock of sample buffer containing 250mM Tris pH 6.8, 8% SDS, 35% Glycerol and 
bromophenol blue at a concentration of 10mg per ml was diluted 1:1 with PBS and 
100mM DTT to make the lysis buffer used for the protein preparations. A stacking gel 
was used to pack the proteins after loading, and a separating gel was used to resolve 
the proteins in the sample according to their relative molecular weight (see Table 1). 
 
Table 1: Gel mixes used for SDS-PAGE 
Seperating gel (x2) 
 7.5% 10% 12.5% 
Acrylamide (ml) 2.5 3.34 4 
1.5M Tris pH 8.8 (ml) 2.5 2.5 2.5 
Pure Water (ml)  4.85 4 3.35 
10% SDS (µl) 100 100 100 
10% APS (µl) 80 80 80 
TEMED (µl) 4 4 4 
Stacking gel (x2) 
Acrylamide (ml) 0.75 
1M Tris pH 6.8 (ml) 0.63 
Pure Water (ml) 3.4 
10% SDS (µl) 50 
10% APS(µl) 75 
TEMED (µl) 10 
 
The standard protocol for the Protean II mini-gel system (Bio-Rad) was used to set up, 
load and run the gels. 15µl-30µl of boiled cell lysate was added to each well, and  5µl 
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of Precision Plus Protein Standard ladder (Bio-Rad) was loaded into the wells next to 
the lysates. The gel tank chamber was filled with running buffer (250mM Tris, 
192mM Glycine and 0.1% SDS) and the gel was run at a constant current of 30mA 
until the samples had passed through the stacking gel, then the current was increased 
to 60mA until the samples had passed through the separating gel, as judged by 
migration of the dye front.  
 
3.3.2.2 Western Blotting 
Following SDS-PAGE the gel was removed from the gel sets and equilibrated in 
transfer buffer (25mM Tris, 192mM glycine and 20% methanol) for 10-20 min. Five 
sheets of filter paper and one sheet of nitrocellulose membrane (Whatman Protran) 
were then soaked in transfer buffer and placed onto the Bio-Rad semi-dry transfer cell. 
The protein gel was then placed on top followed by a further five sheets of soaked 
filter paper. Air bubbles were removed from the sample stack using the roller pin 
exclusion technique in order to ensure successful protein transfer. Protein transfer as 
performed at 12 V for between 30 to 85 min depending on the molecular weight of the 
protein of interest. Once the transfer was complete the membrane was stained with 
ponceau red to ensure successful protein transfer. 
 
3.3.2.3 Immunodetection  
Prior to immunological detection, the nitrocellulose membrane was incubated in 
blocking solution containing 1% BSA (w/v), 1x TBS, 0.2% Triton X-100 and 0.1% 
Tween-20 at room temperature for 2 h in order to inhibit any non-specific antibody 
binding. The membrane was then incubated with the selected primary antibody 
overnight at 4oC on a plate shaker. The following morning the membrane was washed 
twice in antibody-free blocking solution and then twice in PBS before being incubated 
with the appropriate secondary antibody for 1.5 h, diluted to 1:2000 in the secondary 
antibody solution containing 1% BSA (w/v), 1x PBS, 0.2% Triton X-100 and 0.1% 
Tween-20. The nitrocellulose membrane was then washed once in clean antibody 
wash and twice in TBS, 0.2% TritonX-100, 0.1% Tween-20 followed by one final 
wash in TBS. 
 
Enhanced chemiluminescence (ECL) was used to detect the presence of the HRP-
conjugated secondary antibody complexes. The membrane was placed in ECL mix 
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(lumi-light western blot substrate- Roche) for 5 min to ensure complete coverage. 
Excess solution was removed and the membrane placed in Saran wrap prior to 
exposure. 
 
3.4 First strand cDNA synthesis 
Total RNA was transcribed into cDNA using the QuantiTect (Qiagen) reverse 
transcription kit. Genomic DNA wipeout (2µl of 7x) was added to 1µg isolated RNA 
and the volume made up to 14µl with RNAse free water and the sample incubated at 
42oC for 15 min. Reverse transcriptase (1µl), Quantiscript RT buffer (4µl of 5x), and 
1µl primer mix were then added, the sample was mixed and incubated at 42oC for 15 
min and then 95oC for 3 min. 
 
3.5 Polymerase chain reaction (PCR) 
3.5.1 RT-PCR 
For reverse transcriptase PCR we used the Phusion high fidelity DNA polymerase 
(Finnzymes) at the concentration and programme recommended by Finnzymes (see 
Tables 2 and 2a). 2µl of the first strand cDNA synthesis material was sufficient for a 
reaction, the products of which were examined on 1% agarose gels to normalise to ß-
actin expression levels. 
 
Table 2: Finnzymes Phusion Taq RT-PCR Recipe 
Component 50ul reaction 20ul reaction Final Conc 
Water 16.5µl 5.4µl  
5x Phusion Buffer* 10µl 4µl 1x 
10mM dNTPs 1µl 0.4µl 200µM each 
Forward Primer 10µl  4µl 0.5µM 
Reverser Primer 10µl 4µl 0.5µM 
Template DNA 2µl 2µl  
Phusion Taq 0.5µl 0.2µl 0.02U/µl 
* HF Buffer is default but can use GC Phusion Buffer if amplified sequence is GC rich 
 
Table 2a: RT-PCR Programme 
Suggested by Finnzymes for Phusion polymerase 
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                        2 – step protocol   3 – step protocol 
Cycle Step Temp Time Temp Time Cycles 
Denaturation  98oC 30 s 98oC 30 s 1 
Denaturation 
Annealing 
Extension 
98oC 
- 
72oC 
5-10 s 
- 
15-30 s 
98oC  
XoC 
72oC 
5-10 s 
10-30 s 
15-30 s 
 
25-35 
Extension 72oC 
4oC 
5-10 min 
HOLD 
72oC 
4oC 
5-10 min 
HOLD 
1 
Our programme: 98oC 2 min / 98oC 30 s, 63oC 30 s, 72oC 30 s / 72oC 10 min 
 
3.5.2 qPCR 
Quantitative PCR (qPCR) was performed using the Power Syber Green master mix 
(Applied Biosystems) containing the SYBR Green 1 Dye, AmpliTaq Gold® DNA 
Polymerase, dNTPs with dUTP and optimised buffer components at the suggested 
concentrations under the suggested qPCR programme (see Tables 3 and 3a). All 
reactions were set up in triplicate and read from a 96 well plate (see schematic 1). 
 
Table 3: Applied Biosystems Syber Green Reaction Volumes  
                                         1x Reaction      3x Reactions 
Component Volume (µl) Volume (µl) Final Conc 
Water Make up to 25 Make up to 85  
Syber Green 12.5 37.5 1x 
Forward Primer* X X   
Reverse primer* X  X   
DNA 0.5 1.5  
* Forward and reverse primer concentration determined by primer optimisation 
 
Table 3a: Applied Biosystems Syber Green Programme 
Cycle Step Temp Time Cycles 
Step1 95oC 10 min 1 
Step 2 95oC 
60oC 
15 s 
1 min 
40 
Step 3 95oC 15 s 1 
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60oC 
95oC 
15 s 
15 s 
 
Schematic 1: 96 well plate organisation for qPCR analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5.2.1 qPCR Analysis 
Once the qPCR reaction was completed the Ct values (recording representing when 
the flourescence from double stranded DNA dye incorporation could be detected) were 
entered into a DART analysis programme, in order to calculate the relative fold 
changes in gene expression of target genes normalised to those of ‘house keeping’ 
genes such as ß-actin. The values were then transferred into an Excel spreadsheet for 
downstream analysis and graphical representation. 
 
3.5.3 Primers 
3.5.3.1 Primer Optimisation for qPCR 
For optimum qPCR efficiency the primers used were subjected to reaction 
optimisation through the four set reactions recommended by Applied Biosystems (see 
Key: A1-3 Sample 1, A4-6 Sample 2, A7-9 Sample 3 and A12 No template control. 
B is a duplicate of A but with different primers to test a different gene 
  A 
 
  B 
 
  C 
 
  D 
 
  E 
 
  F 
 
  G 
 
  H 
     2         3         4           5         6         7         8        9       10      11      12 
 
  1 
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Table 4). The lowest Ct value indicates the most efficient reaction, therefore the 
primer sets chosen by their lowest Ct value. 
 
Table 4: Primer optimisation reactions 
Reaction 1 Reaction 2 Reaction 3 Reaction 4 
9µl Water 6µl Water 6µl Water 3µl Water 
12.5µl Syber Green 12.5µl Syber Green 12.5µl Syber Green 12.5µl Syber Green 
1.5µl PF 1.5µl PF 4.5µl PF 4.5µl PF 
1.5µl PR 4.5µl PR 1.5µl PR 4.5µl PR 
0.5µl DNA 0.5µl DNA 0.5µl DNA 0.5µl DNA 
 
3.5.3.2 Primer Sequences 
The mouse ß-actin primers were designed by Jennifer McKenzie, the human ß-actin by 
Amanda Carr and the human Toll-like receptors, Glypicans, Syndecans were taken 
from [139]. I designed the remaining primer sets, and checked them online using 
Primer3 for hairpins etc., and blasted them with the NCBI Blast software to ensure no 
significant similarity to alternate targets. Primers were ordered from MWG Operon 
and stored at -20oC as a 100 pmol/µl stock. 
 
Table 5: Primer Sequences 
Name Forward 5’   3’ Reverse 5’   3 
Mouse ß-actin TCCAAGTATCCATGAAATAAGTGG GCAGTACATAATTTACACAGAAGC 
Human ß-actin TCCCTGGAGAAGAGCTACGA AGGAGGGAAGGCTGGAGGAG 
Mouse LBP CCTTCTCAACAGCCTCTACC GCACCCAAGTATAAGAAGTCC 
Human LBP GTCTCAGCATCTCCGACTCC AAGTCTCCCGACATGTCCAC 
Mouse ikBα CAACCTGCAGCAGACTCCACTC ACACGTGTGGCCATTGTAG 
Human ikBα CCAGGGCTATTCTCCCTACC GCTCGTCCTCTGTGAACTCC 
Mouse VEGFa GACTTGTGTTGGGAGGAGGA TCTGGAAGTGAGCCAATGTG 
Human VEGFa CTACCTCCACCATGCCAAGT CACACAGGATGGCTTGAAGA 
Mouse A2aR TCAACAGCAACCTGCAGAAC GGCTGAAGATGGAACTCTGC 
Human A2aR SAME AS MOUSE GCCAGGAGACTGAAGATGGA 
Mouse TGFß1 TTGCTTCAGCTCCACAGAGA TGGTTGTAGAGGGCAAGGAC 
Human TGFß1 GGGACTATCCACCTGCAAGA CCTCCTTGGCGTAGTAGTCG 
Human TLR1 GGTCTTGCTGGTCTTAGGAGAGAC CTGAAGTCCAGCTGACCCTG 
TAGCTTCACG 
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Human TLR2 GGCCAGCAAATTACCTGTGTG CTGAGCCTCGTCCATGGGCCACTC 
Human TLR3 CGGGCCAGCTTTCAGGAACCTG GGCATGAATTATATATGCTGC 
Human TLR4 TGCAATGGATCAAGGACCAGAGGC  GTGCTGGGACACCACAACAATCACC 
Human TLR5 CCTCATGACCATCCTCACAGTCAC GGCTTCAAGGCACCAGCCATCTC 
Human TLR6 CCAAGTGAACATATCAGTTAA 
 
ACTTTAGGGTGC  
CTCAGAAAACACGGTGTACAAAG 
CTG 
Human TLR7 CTCCCTGGATCTGTACACCTGTGAG  CTCCCACAGAGCCTTTTCCGGAGCT 
Human TLR8 GTCCTGGGGATCAAAGAGGGAAGAG CTCTTACAGATCCGCTGCCGTAGCC 
Human TLR9 GCGAGATGAGGATGCCCTGCCCTACG TTCGGCCGTGGGTCCCTGGCAGAAG 
Human TLR10 CAGAGGTCATGATGGTTGGATG  GACCTAGCATCCTGAGATACCAG 
 
GGCAG 
Human GPC1 CGATGACCACTTCCAGCACC CCGAGAGAGCTGCGCCTGCGG 
Human GPC2 ACTGGGACACGACCTGGAC GGGCTGAGAGGGAGAGAATG 
Human GPC3 CCAAGAGGCCTTTGAAATTGT TGACAGCCTGTTTCCAGTCA 
Human GPC4 AGTGTGGTCAGCGAACAGTG GGCGAGCCCAGAAGTCATTTA 
Human GPC5 CACTTTTCTGCAGGCACTCA GGCTTTGTGTGGGTGTTCTT 
Human GPC6 CCAGGACCTCTTCACAGAGCTG TGGGCAGTACAGCATCTTCA 
Human SDC1 GCTCTGGCTCTGGCTGTGC CTGTGTGGGGAGTGTGAAGG 
Human SDC2 AAGACATGTACCTTGACAACAG AACTCCACCAGCAATGACAG 
Human SDC3 CAACCAGACACAGCCAATGAG GACCAAGAAGGCAGCAAAGA 
Human SDC4 ACGATGAGGATGTAGTGGGG GGGTTTCTTGCCCAGGTC 
 
 
3.6 Genetic knock down 
3.6.1 siRNA preparation 
Human syndecan-2 siRNA was purchased from Ambion (silencer siRNAs 12433, 
12528 and 12618) and Santa Cruz (sc-41045) and made up to a 20µM stock in RNAse 
free water. Control siRNA-A (Santa Cruz) was used as the scrambled control and was 
made up to same stock concentration in RNAse free water.  
 
 
3.6.2 Cell transfection optimisation 
Day 1, Hela cells were split and plated into antibiotic free cell media (DMEM 10% 
FCS) in 12-well tissue culture plates at approx 40% confluence in the morning. After 6 
h they were transfected with 100pmol of selected siRNA (Ambion supplied 3 separate 
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siRNAs, which were tested alone, in pairs and as the complete pool. Santa Cruz 
supplied 3 siRNAs already in a pool) using Oligofectamine (Invitrogen) transfection 
reagent. The cells were left at 37oC, 5% CO2 overnight. The following day (day 2) 
cells were split 1:2 and replated, and after 6 h the transfection was repeated as before. 
The following morning (day 3) the culture media were changed and cells left for the 
day at 37oC in 5% CO2. On day 4 the cells were placed into starvation serum with no 
FCS. After 48 h (day 6) the cells were treated with LBP, LBP+LPS or LPS at various 
concentrations for 30 min before being lysed in SDS-PAGE sample buffer and boiled 
at 95oC for 5 min. 
 
3.7 Analysis of signalling  
Cell lysates were resolved by 10% SDS-PAGE and immunoblotted for phosphoERK 
and total ERK (Cell Signalling 1:2000) according to the western blotting protocol 
reported earlier. Scrambled control siRNA responses were compared to syndecan-2 
knock-down to identify whether LBP responses had any dependence on syndecan-2 
expression. 
 
4. Angiogenesis Assays 
4.1 Matrigel Tube Assay  
To assess the angiogenic capability of LBP we decided to use the Matrigel assay. 
Fully confluent HUVEC were trypsinised and the cells pelleted and resuspended in 
1ml EGM2 media before being counted using a 0.0025mm2 Neubauer 
Haemacytometer. BD Matrigel (growth factor reduced, BD Biosciences) was thawed 
slowly on ice and 50 µl added to individual wells of a 96 well plate. The plate was 
then kept at room temperature for 15 min to allow the Matrigel to set. 105-106 HUVEC 
were then seeded on top of the Matrigel and EGM2 culture media was added to make 
the volume up to 100 µl. Gels were then divided into control PBS, and 10 ng LBP ± 50 
µg LPS, with cells returned to culture overnight to be imaged after 12-16 h. 
 
 
4.1.1 Matrigel Imaging and Analysis 
To generate images the gels were photographed using a Leica epifluorescent 
microscope. 24-bit monochannel images were taken at 2x magnification under 
brightfield conditions. The image was then analysed by counting the number of 
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sprouts, branches and closed loops formed. An average of the gels for each treatment 
was then plotted and normalised to control conditions for statistical analysis. 
 
4.2 Aortic Ring Assay 
Thoracic aortas were dissected from wild type rats aged 2 weeks and placed into 
Optimem media (Gibco). The extraneous fat surrounding the vessel was carefully 
removed and any blood flushed out with a 25G needle and syringe. The tissue was 
then transversely sliced into aortic rings approximately 0.5 mm width. The rings were 
then mounted into wells of a 96 well plate in a Collagen I:E4 media mix at 
concentrations of 1.2 mg/ml (collagen I from rat tail, Sigma) and incubated at 37oC, 
5% CO2 for 1 h. After this time the gel had fully polymerised and the ring was 
securely embedded. 150 µl of aortic ring media (E4 + 10% FCS) was gently added and 
the plate was placed back into the incubator. Two days later the ring was removed 
from the incubator and allowed to equilibrate to room temperature for 10 min. 120 µl 
of media were then removed and replaced with fresh ring media ± treatments as shown 
in figure legends. Ring samples were left for a further week with fresh medium (± 
treatments) applied every 2 days to stimulate sprouting. 
 
4.2.1 Aortic Ring Staining 
To assess vessel sprouting the samples were stained with isolectin-B4 (Vector). First 
the rings were fixed in 4% PFA/PBS for 20 min at room temperature before being 
permeabilised with 0.5% Triton X-100/PBS for 30 min and then immersed in a 
blocking solution (1% BSA, 0.5% Triton X-100/PBS) for a further 30 min. The 
samples were then incubated in fresh blocking solution supplemented with a 1:200 
dilution of isolectin-B4 FITC on a plate shaker overnight at 4oC. The following 
morning the samples were washed extensively in PBS and imaged immediately.  
 
 
 
4.2.2 Aortic Ring Imaging and Analysis 
To generate images the rings were photographed using an inverted Leica 
epifluorescent microscope. Isolectin-B4 FITC images were taken using a GFPA filter 
(488nm) with 5x magnification, which was usually sufficient for observing the entire 
ring and sprouts in one image. The image was then exported to ImageJ and inverted. 
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The ring and sprouts were sketched and a mean intensity value recorded. The ring was 
then isolated and its own intensity value recorded. The ring value was then subtracted 
from the ring + sprout value. This value was termed the sprout intensity. Treatments 
could then be compared for their sprout growth, and fold changes calculated by 
normalising to the control samples. 
 
4.3 Metatarsal Assay 
Metatarsal bones were dissected from wild type E16-18 age pups and placed onto 
0.1% gelatin-coated 24 well plates. 180 µl of 10% DMEM media was gently pipetted 
into each well and the plates carefully transferred to an incubator at 37oC, 5% CO2 for 
2 days. On the third day samples were assessed to ensure they had settled on the 
bottom of the dish, those that had not were not used. 120 µl of media was removed and 
180 µl fresh media (with appropriate treatments) was added. The samples were left for 
9 days with replenishment of media and agonists every 3 days.  
 
4.3.1 Metatarsal staining 
On the last day of the assay the media was carefully removed and the sample was 
gently washed twice in PBS. The tissue was then fixed in 4% PFA for 15 min at room 
temperature. The samples were then washed three times in PBS, after which the 
samples were placed into blocking buffer (10% BSA, 0.1% Triton in TBS) for 1 h. 
The blocking buffer was then removed and the samples put into fresh blocking buffer 
with PECAM-1 (1:200) antibody overnight at 4oC. The next day the samples were 
washed three times in antibody-free blocking buffer and once in TBS. Anti-rabbit 
Alex 594 (1:200) in blocking buffer was then added to the samples for 1 h at room 
temperature. The samples were then washed three more times in antibody-free 
blocking buffer (each wash lasting 10 min) and then twice in TBS. 
 
 
 
4.3.2 Metatarsal Imaging and Analysis 
To generate images the samples were viewed using an upright stereoscope. PECAM-1 
staining was observed using a RFP2 filter (594nm) and 24-bit monochannel images 
were taken at 2.5 x magnification to enable all of the tissue and sprouts to be seen. The 
images were then exported into the Imaris software where a set background level was 
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subtracted to minimise plastic autofluorescence, and the rendering programme was 
used to track the tissue sprouts. The data readouts (vessel area, volume, branch points 
etc) were then exported to Excel, and graphs constucted of the data to compare treated 
to control samples. 
 
5. Statistics 
All experiments were performed a minimum of three times and the data subjected to 
standard deviation, standard error of the mean and student TTest analysis where 
P<0.05 was taken as significant. 
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Chapter One 
 Characterisation of the VLDLR-/- Mouse Retinal Vasculature 
 
1.1 Background 
The VLDLR is an 86kDa transmembrane protein belonging to the low-density 
lipoprotein (LDL) receptor family [147]. There is high interspecies cDNA 
conservation with human, mouse, rabbit and rat displaying >95% sequence similarity 
suggesting an important physiological role for this receptor [148]. Two isoforms of the 
VLDLR have been identified in humans, both of which display tissue-specific 
expression, with isoform one being expressed richly in the heart and skeletal muscle 
whilst isoform two appears more disperse in the cerebellum, adrenal glands and 
ovaries [147, 148]. Originally it was thought that the VLDLR simply functioned to aid 
triglyceride metabolism, however it has since been shown to behave as a receptor for 
many ligands including thrombospondin-1 and Reelin [149, 150]. Mutations in the 
VLDLR have recently been associated with cerebellum hypoplasia, mild cerebral gyral 
simplification and mental retardation [151].  
 
The VLDLR-/- mouse exhibits angiogenic retinal vascular abnormalities with several 
groups reporting the pathogenic progression to mimic certain characteristics of human 
eye diseases such as MacTel and retinal angiomatous proliferation (RAP) [52].  
Studies have shown the VLDLR protein to be expressed by the deeper plexus of the 
retina and the RPE with in vitro experiments demonstrating that  
VLDLR-/- retinal vascular endothelial cells (RVECs) form 3-11 times more capillaries 
in culture and have a 20-100% increase in proliferative rate [148-150, 152]. These 
studies and the knock out mouse phenotype suggest that the VLDLR is required for 
inhibition / regulation of angiogenesis in the retina. This is supported by one of the 
ligands for VLDLR, thrombospondin-1 being known to be anti-angiogenic and by 
genetic analysis identifying VLDLR polymorphisms as a contributing factor in the 
development of AMD [153-156].  
 
1.1 Aim 
The VLDLR-/- mouse displays abnormalities in its retinal vessels, so was chosen 
alongside the Grhl3CT/J Curlytail mouse (CT) and Retinal-dystrophic-1 (RD1) mouse 
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to be one of the models used in a microarray screen to identify new genetic targets in 
retinal vascular disease. Genetic analysis showed there were sixty-two genes 
commonly altered in all three of the mouse models selected.  The VLDLR-/- mouse is 
considered to be an angiogenic mouse model and was the model where LBP was most 
markedly up regulated. The first aim of this study was therefore to investigate the 
potential role of LBP in the VLDLR-/- mouse retinal vasculature.  
 
2. Results 
2.1 Gene validation 
The vascular microarray identified 62 genes as commonly changing in all three of the 
mouse models. Genes were selected for validation and further investigation based 
upon their function and / or the level of change in their expression. We selected six 
genes for q-PCR validation (table 6). 
 
GENE NAME FUNCTION 
LBP Lipopolysaccharide 
Binding Protein 
Binds to LPS and presents it to CD14 & TLR4. 
Atp8b1 ATPase  8b 1 Transporter for phosphatidylserine and 
phosphatidylethanolamine, shuttling them from 
one side of bilayer to other. 
CRIM1 Cysteine rich 
transmembrane 
BMP regulator-1 
 
Role in capillary formation and maintenance 
during angiogenesis 
RSBN1 Round Spermatid 
basic protein-1 
Spermatogenesis 
 
GLCCI1 Glucocorticoid 
induced transcript-1 
Uncertain 
OAZ2 Ornithine 
decarboxylase 
antizyme-2 
Regulates polyamine synthesis.  
 
Table 6: Microarray Genes selected for q-PCR Validation 
 
Neuroretina tissue was dissected from 16wk old VLDLR-/- and CT mice alongside 
12wk old RD1 mice. RNA was isolated and the quality confirmed by the sample 
having a value of approximately 2 in the 260/280 absorbance recording using a 
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Thermo Scientific Nanodrop machine. Genomic DNA was then removed and first 
strand cDNA synthesis performed. Gene primers to six of the sixty-two genes 
identified in the microarray were designed, each containing >50% GC content and 
having a melting temperature (Tm) of 60oC. All primer pairs underwent q-PCR 
optimisation (Methods section 3.5.2) and were used at their optimal forward : reverse 
ratio to ensure minimal primer dimer formation (as indicated by a clean single peak in 
the dissociation curve, figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: q-PCR Dissociation Curve. An example of a clean q-PCR primer dissociation curve. If 
there were primer dimer formation there would be a smaller peak visible between 70-75oC. 
 
 
Two of the six genes analysed were found to confirm the microarray results, one of 
which was LBP, which demonstrated a much higher fold change in expression than the 
other validated gene Oaz2, 8-13 times increase compared to 2.5-3 (figure 12). 
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Curiously, LBP was only found to be elevated in the VLDLR-/- and CT mice, and not in 
the RD1 mouse. This is interesting because the VLDLR-/- and CT mice are considered 
to be models of retinal vascular angiogenesis [159] whereas the RD1 mouse does not 
appear to be angiogenic and is instead considered to be a model of retinal vascular 
remodelling [159]. As LBP was most markedly up-regulated (P <0.001) in the VLDLR-
/- mouse it was decided that further work investigating LBP expression in the retina 
would use this mouse model.   
 
2.1 LBP and VEGF expression in the developing and adult mouse retina 
The microarray was performed on 16wk old VLDLR-/- mice, when the vascular 
abnormalities were fully developed and the disease was established. Given that 
vascular abnormalities are evident in the VLDLR-/- mouse as early as P14 [157] we 
wanted to determine whether LBP was up-regulated earlier in the development of 
vascular pathogenesis. Changes in gene expression at a younger age could suggest a 
causative role for LBP in disease development. Due to the established role of VEGF in 
vascular disease we also decided to measure the changes in VEGF-A expression in the 
VLDLR-/- mouse, as any temporal similarities or differences in LBP and VEGF-A 
expression would be of potential interest. Neuroretina tissue was dissected from P0 – 
16wk old C57B6 wild type and VLDLR-/- mice. RNA was isolated and the quality 
confirmed. Genomic DNA was then removed and first strand cDNA synthesis 
performed (P0-17 samples were prepared by Dr. Xiaomeng Wang, >P17 samples were 
prepared by myself). Primers were designed to detect all splice variants of VEGF-A 
and optimised as discussed previously (Methods section 3.5.2). LBP and VEGF-A 
expression were then quantified at the mRNA level using q-PCR. Gene expression 
was normalised to age-matched ß-actin levels, and then again normalised to model 
mouse matched P0 (e.g. C57B6 wild type P14 LBP expression was first normalised to 
C57B6 wild type P14 ß-actin and then normalised to C57B6 wild type P0 LBP) levels 
in order to reveal changes in gene expression during development of the retinal 
vasculature.   
 
The results show (figure 13) that in C57B6 wild type mice LBP expression is very low at all 
time points, apart from during the development of the deeper vessel plexus (P10-14) when 
there is a 30-50 fold increase in its expression, due to the increased variation in expression 
levels at P14-21, this failed to reach significance. The VLDLR-/- mouse appeared to show  
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Figure 12: q-PCR Validation of Microarray Genes. Six genes were selected from the sixty-two genes 
identified in the vascular microarray analysis. Neuroretina tissue was dissected from 12wk old Grhl3CT/J 
Curlytail mice (CT), 16wk old Retinal Dystrophic-1 mice (RD1) and 16wk old very-low density 
lipoprotein receptor knock out (VLDLR-/-) mice. RNA was isolated and cDNA synthesised from the 
tissue samples. Q-PCR analysis was then performed, comparing age-matched C57B5 wild type (WT) 
mice and normalising to internal ß-actin expression. (n=3). Standard error of the mean bars shown. p= 
<0.05* <0.01** <0.001***  
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increased LBP expression at all ages analysed, although the large increases (40-160 
fold) in LBP expression from P14-P21, failed to reach statistical significance. 
Comparatively smaller (10-20 fold), but statistically relevant (p = <0.05) increases in 
LBP expression were observed at P4 and P8, prior to the formation of vascular 
abnormalities. 
 
VEGF-A is expressed at much lower levels than LBP in the retina. VEGF-A expression 
appeared to remain approximately constant in the C57B6 wild type mouse during 
development and than decreased following maturation of the retinal vasculature at 
P21. Significantly increased levels of VEGF-A expression were observed in the 
VLDLR-/- mouse at all of the ages examined with the largest increase (2-4 fold) 
observed at P10-17, which, as previously mentioned, is when the deeper vessel plexus 
forms and when the onset of vascular abnormalities is known to occur. It is interesting 
to note that the increase in LBP expression occurs at approximately the same time as 
the increase in VEGF-A, this could suggest interplay between the two genes. 
 
2.2 Vascular abnormality development in the VLDLR-/- mouse 
It is known that the VLDLR-/- mouse begins to develop vascular abnormalities from 
P14 [145], the time of peak expression of both LBP and VEGF-A. We next 
investigated the generation of diseased vasculature within these mouse retinas in order 
to determine whether the vascular abnormalities could be detected at younger ages. 
Neuroretina tissue from C57B6 wild type and VLDLR-/- mice aged 3wks, 6wks and 
9wks was dissected and flatmounts prepared. To visualise the vasculature the tissue 
was fluorescently immunostained with antibodies against collagen-IV and imaged by 
epi-fluorescence. The results show (figure 14) that in the VLDLR-/- mice, the vascular 
abnormalities were present at all ages analysed, with the number of vascular 
abnormalities increasing with age, consistent with previous reports [159].  
 
2.3 LBP expression in the retina 
LBP is a secreted glycoprotein primarily expressed by hepatocytes and macrophages 
[158]. However our microarray analysis, which detected an up regulation in LBP, was 
performed on isolated retinal vessels suggesting endothelial (or associated cell) 
expression of LBP.  
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Figure 13: q-PCR Analysis of LBP and VEGF-A p0-16wk C57B6 wild type vs VLDLR-/- Mice. 
Neuroretina tissue was dissected from p0-16wk old Very-Low Density Lipoprotein Receptor Knock 
Out (VLDLR-/-) mice. RNA was isolated and cDNA synthesised from the tissue samples. q-PCR 
analysis was then performed to determine LBP and VEGF expression compared to age-matched C57B6 
wild type mice, and normalised to internal ß-actin expression. (n=3) p= <0.05* <0.01** <0.001***  
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Figure 14: 3-9wk old C57B6 wild type and VLDLR-/- Mouse Retina Flatmounts stained with 
Antisere to Collagen-IV. Neuroretina tissue was dissected from 3-9wk old wild type (WT) and very-
low density lipoprotein receptor knock out (VLDLR-/-) mice. The tissue was flatmounted and incubated 
with a collagen-IV antibody to label the vessels. Images were taken using a  Leica epifluorescent 
microscope to observe the vascular pathology (arrowed). (Scale bars 50µm, zoom 20µm)  
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In order to determine the site(s) of LBP expression in the retina, eyes were isolated 
from 16wk old C57B6 wild type and VLDLR-/- mice, the cornea, iris and lens were 
removed, and the ‘eye cup’ fixed in paraformaldehyde (PFA) before being embedded 
in optimal cutting temperature (OCT) compound and sectioned. To visualise LBP 
expression in the retina the tissue sections were immunostained with an antibody 
against LBP and then washed with diaminobenzidine (DAB), which yields a brown 
stain where the LBP antibody was bound.  
 
The staining pattern suggests that LBP is expressed throughout the retina, with no 
obvious site of cellular enrichment, or differences between the C57B6 wild type and 
VLDLR-/- mice (figure 15). There was little staining on the photoreceptor layers, but 
most prominent staining in the retinal ganglion cell layers and a striated staining in 
outer nuclear layer (ONL), which could suggest some Müller cell enrichment.  
 
 
3. Chapter Discussion 
The up-regulation of LBP observed in the microarray was validated in the VLDLR-/- 
and CT models but not in the RD1 mouse. As previously mentioned, and as described 
recently by our group [152] the RD1 mouse has been shown to have limited new 
vessel formation, making it a model for vascular remodelling rather than angiogenesis 
[150], whereas the VLDLR-/- and CT mice are more representative models of 
angiogenesis [152]. Therefore for LBP to be validated only in the angiogenic models 
suggests it is most likely to have a hypothetical role in blood vessel production and 
growth, rather than remodelling.  
 
This notion is further supported by the LBP and VEGF-A VLDLR-/- timecourse 
analysis, which showed that LBP is up-regulated in the retinas of C57B6 wild type 
mice during the physiological angiogenesis required for vascular development and in 
VLDLR-/- mice prior to the pathogenic vascular observations. Thus, the up-regulation 
of LBP in both normal and disease models is not a consequence of the vascular 
changes. There appears to be a similar pattern in LBP and VEGF-A expression in the 
developing retina, suggesting some co-ordination of regulation of the two genes. It 
could be that both genes are under the same transcriptional initiation signals / 
regulators, or as the increase in LBP expression slightly precedes an increase in 
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Figure 15: LBP Immunostaining of C57B6 wild type and VLDLR-/- Mouse Eye sections. 
Eyes were dissected from 16wk C57B6 wild type (WT) and very-low density lipoprotein receptor 
knock out (VLDLR-/-) mice. The cornea and lens were removed and the ‘eye cup’ embedded in 
OCT for sectioning. The tissue sections were then incubated with an antibody for LBP and 
counter-stained with DAB to visualise LBP localisation as brown. The samples were then 
imaged using a light microscope to assess LBP staining enrichment. LBP appeared to be 
expressed throughout the retina with some enhanced staining observed in the retinal ganglion 
cell layer (RGC) and some striated staining in the outer nuclear layer (ONL), arrowed. There 
were no striking differences between the WT and VLDLR-/ mice although there was some 
enrichment in visible retinal angiomatous proliferation (RAP) lesions. Negative antibody staining 
protocols confirmed the staining. Inner nuclear layer (INL), Outer plexiform layer (OPL), 
Photoreceptors (PR), Choroid (C). The dark stained layer represents the retinal pigment 
epithelium (RPE) and Bruch’s membrane. (Scale  20µm, zoom 10µm).  
 
 
 
 
 
    WT                                              VLDLR-/-   
 
 75 
VEGF-A expression it could be that LBP is required for the later induction of VEGF-A. 
LBP has been found to induce VEGF signalling under angiogenic switch conditions 
[130] (Introduction, section 3.3), however the mice used for this experimental analysis 
were notionally pathogen free and thus were free from LPS, suggesting that if LBP 
does induce VEGF, then it may not be via the angiogenic switch signalling pathway.  
 
In newborn C57B6 wild type mice, levels of LBP expression in the developing and 
adult retina appear to be low, only increasing at P10-14. LBP expression is 
significantly higher in the VLDLR-/- mouse, with q-PCR analysis suggesting a dramatic 
fold increase (30-160) during development. This is in contrast to VEGF-A, which 
although increased in the VLDLR-/- mouse is elevated by a much smaller fold amount 
(2-4). This suggests that if LBP does have an effect on retinal neovasculaturisation it 
may not be as potent as VEGF-A. LBP is expressed constitutively at 2-5ng/ml in 
circulating plasma [160, 161], which is substantially higher then VEGF 
(approximately 30pg/ml) [94]. However, upon infection, LBP concentrations have 
been reported to increase up to 50µg/ml within 36h [161]. But during infection LBP 
will often be in complex with LPS and not circulating freely. LBP is mostly 
synthesised by the liver and macrophage cells, but local production by the eye during 
retinal vascular development (as revealed by the microarray and q-PCR analysis), 
suggests that in the absence of infection (and by association, LPS), LBP may have 
some angiogenic role. The fact that LBP is elevated in the VLDLR-/- mouse argues that 
it contributes to the onset of pathological angiogenesis in the retina of these animals, 
and is consistent with the increase in expression of other established angiogenic 
factors such as VEGF. 
 
Retinal flatmount analysis comparing 3-9wk old C57B6 wild type and VLDLR-/- mice 
confirmed that vascular abnormalities are present and can be detected in p21 VLDLR-/- 
mice, supporting findings elsewhere [154, 155] and illustrating that the vascular 
changes occur alongside the alterations in gene expression we detected using q-PCR.  
 
LBP was originally detected in our microarray analysis, which was performed on 
isolated retinal vessels. The vessels were isolated through neuroretina dissection and 
digestion with collagenase and dispase, the tissue was then incubated with rat 
antibodies for the vascular marker PECAM1 before being mixed with magnetic beads 
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coated with an anti-rat antibody [152]. The anti-rat antibody detected the rat-PECAM1 
and upon positioning of the sample near to a magnet the PECAM1 positive cells (i.e. 
vessels) were separated. However, there is no mention in the literature of LBP being 
expressed by endothelial cells. Immunostaining of C57B6 wild type and VLDLR-/- 
retinal sections was inconclusive in this respect, revealing that LBP is expressed 
throughout the retina with no specific enrichment in the vasculature. However there 
did appear to be an enrichment of LBP in the ONL of the VLDLR-/- mouse, and the 
somewhat striated staining pattern could correspond to the extensive Müller cell 
projections known to reside in this layer. The notion that Müller cells in the vessel 
prep might explain the presence of LBP in the microarray study, is supported by cell 
culture q-PCR analysis showing that LBP was not expressed by a variety of 
endothelial cells (HUVEC, GPNT and RBE4), but was expressed by the MIO-M1 
Müller cell line. Although the retinal vessel prep was clearly enriched for endothelial 
cells it is inevitable that there would be other vascular supportive cell types 
contaminating the preparation (e.g. pericytes, smooth muscle cells and Müller cells). 
Müller cells are known to be activated during retinal disease, changing their phenotype 
and secreting a range of angiogenic factors including VEGF, TGFß and PDGF, that 
may all contribute to pathological neovascularisation [162]. Should LBP prove to 
directly affect vascular behaviour, those Müller cells in close proximity to the retinal 
vessels would be ideally placed to influence angiogenesis, as a source of secreted 
LBP.  
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Chapter Two  
Investigation of the Angiogenic Potential of LBP 
 
  
1.1 Background 
LBP is an innate immune system glycoprotein, which binds to LPS, a component of 
gram-negative bacteria such as E. coli and presents it to CD14 antigen presenting cells 
to activate TLR4 signalling to induce an inflammatory response [106, 151]. In all of 
the experiments carried out investigating the role of LBP, none have reported it to 
have an effect on vascular growth.  
 
LBP was the third most up regulated protein in the microarray analysis of three mouse 
models (VLDLR-/-, RD1 and CT) of retinal vascular disease. Further characterisation of 
the angiogenic VLDLR-/- model confirmed LBP as being up-regulated prior to disease 
onset and around the same time as an increase in VEGF expression. RT-PCR analysis 
has also shown LBP to be expressed in Müller cells, which are known to be activated 
in pathogenic conditions in the retina [73, 162]. Our observations, alongside known 
associations between immunity and angiogenesis (see Introduction 6.3), suggests that 
LBP could have an as yet uncharacterised role, independent of LPS, affecting vascular 
behaviour. 
 
1.2 Aim 
The aim of work in this chapter was to identify whether LBP has another role outside 
of its function in inflammatory responses of the innate immune system. Specifically, 
does LBP exhibit any effects on vascular proliferation / angiogenic behaviour?  
 
2. Results 
2.1 Limulus Amebocyte Lysate (LAL) assay 
All experimental systems needed to be demonstrably free of LPS in order to 
investigate whether LBP has biological activity, independent of LPS. In 1956 it was 
reported that horseshoe crab blood would turn into a semi-solid gel upon exposure to 
endotoxin (e.g. LPS) due to a coagulogen clotting factor within their amebocyte cells 
[165]. When infected with endotoxin the horseshoe crab ambeocytes release the 
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coagulogen in order to encase the bacteria and prevent it from spreading further into 
the animals circulatory system [165]. This biological mechanism forms the basis of the 
LAL assay [158] (figure 16). Studies have shown that a minimum of 10pg/ml LPS is 
required to induce a cellular response [165]. The LAL assay has a sensitivity of 
3pg/ml endotoxin, therefore as all cell media samples collected from plates during the 
experiments as well as the treatment solutions, culture media and wash buffers tested 
negative using LAL, we can say with confidence that LPS was absent from all 
experiments or that it was below the threshold needed for signalling activation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Limulus Amebocyte Lysate (LAL) Assay Schematic. A Schematic to illustrate the 
methodology of the Limulus Amebocyte Lysate (LAL) Assay approved by the American Food and 
Drug Administration (FDA) to test products for endotoxin contamination.  
 
2.2 Matrigel assay 
The Matrigel assay is a well-established in vitro angiogenesis assay using HUVEC in 
a semi-solid growth matrix (Matrigel) to assess whether a treatment has an effect on 
vessel sprouting, branching and network complexity [166, 167]. The HUVEC were 
seeded onto a growth factor reduced Matrigel support, treated as desired (PBS control, 
10ng/ml LBP, 10ng/ml LBP + 1µg LPS or 1µg LPS), incubated for 12-16h, imaged 
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and analysed for number of sprouts, branch points and closed loops. HUVEC have 
been reported to alter their protein expression profiles as they are cultured (e.g. CD14 
expression decreases dramatically past passage five) [168], therefore the Matrigel 
assays were performed using passage two HUVEC to ensure maximal in vivo ‘like’ 
protein expression.  
 
The results showed that 10ng/ml LBP (bought as a recombinant protein from R&D 
Systems, with 10ng/ml chosen as it was reported by R&D systems to have maximal 
effect in an inflammatory assay) was able to increase sprouting, branch points and 
closed loop formations (figure 17). However, upon addition of 10ng/ml LBP + 1µg/ml 
LPS this increase appeared to be inhibited as we observed sprout, branch and loop 
numbers similar to basal condition numbers. If the HUVEC used in the assay 
expressed CD14, which is likely, the LBP + LPS treatment would be expected to 
induce an inflammatory response. Therefore LPS might have inhibited the pro-
angiogenic effects of LBP in one of two ways – 1) by binding to LBP and promoting 
an inflammatory response and 2) by binding to and sequestering LBP, thereby 
preventing it from signalling independently to induce vascular growth. 
 
Interestingly addition of 1µg/ml LPS alone appeared to decrease the observed sprouts, 
branches and closed loops suggesting that the LPS endotoxin is able to suppress 
HUVEC tubulation. However, 1µg/ml LPS would correspond to a severe infection and 
it may be that such high concentrations of LPS are toxic to HUVEC.  
 
2.3 Aortic ring assay 
The aortic ring assay is an ex vivo tissue based assay routinely used to assess the 
angiogenic activity of natural or synthetic molecules [169]. Aortic tissue was dissected 
from 2wk old C57B6 wild type mice and embedded in a collagen-I gel. The tissue was 
then incubated for 2 days and assessed for fibroblast sprouts, which indicated the 
tissue was alive and able to grow. The rings were then treated with the desired 
treatment (PBS, 10ng/ml LBP, 20ng/ml LBP, 50ng/ml LBP, 10ng/ml LBP + 1µg/ml 
LPS, 20ng/ml LBP + 1µg/ml LPS, 50ng/ml LBP + 1µg/ml LPS, 1µg/ml LPS, 20ng/ml 
LBP + 50ng/ml VEGF, 50ng/ml VEGF + 1µg/ml LPS and 50ng/ml VEGF) for 6 days 
(fresh media + treatment every 2 days). After 6 days the rings were stained with 
antibodies to detect isolectin-B4 and imaged. The image was inverted using ImageJ  
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Figure 17: HUVEC (passage 2) Matrigel Angiogenesis Assay. HUVEC were seeded onto growth 
factor reduced Matrigel (BD) at 2x105/ml cell density. Treatments were then added (PBS control, 
10ng/ml LBP, 10ng/ml LBP + 1µg/ml LPS or 1µg/ml LPS and the gels incubated overnight at 37oC 5% 
CO2. The gels were imaged using a Lecia epifluorescence microscope under brightfield conditions. 
Sprouts, branch points and closed loops were counted manually. Student’s t-test was performed and 
standard error of the mean calculated p = <0.05 * <0.001 ** <0.0001 ***  (n=4). 
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software and the sprouts traced to calculate any changes in the vascular area covered 
(figure 18).  
 
The aortic ring results (figures 19 and 20) supported the previous Matrigel 
observations. Increasing the concentration of LBP increased the size of the vascular 
area in a dose dependent manner with the highest concentration of LBP we tested 
(50ng/ml) giving similar amounts of vascular growth to that observed with 50ng/ml 
VEGF.  
 
The presence of LPS with any concentration of LBP markedly inhibited vascular 
growth induction, with mean vascular area size similar to control levels, and as before, 
addition of LPS alone appeared to inhibit basal vascular growth. Interestingly, LPS 
appeared at times to inhibit VEGF induced vessel growth, although this effect varied 
substantially and was not statistically significant. The observation that LPS inhibits 
both VEGF and LBP was unexpected. As previously mentioned LBP + LPS could 
induce an inflammatory response in the tissue, thus inhibiting vascular growth or LPS 
could be sequestering LBP, therefore preventing its independent activity. The VEGF 
inhibition by LPS is not so easy to explain. It could suggest a common modality 
between LBP and VEGF with some overlap in the signal cascades induced. 
Interestingly, we observed a significant number of unidentified cell types in the LBP + 
VEGF treated tissue that were not present in the cultures only treated only with VEGF. 
This shows that LBP, but not VEGF promotes migration of non-vascular cell type(s) 
from the aortic ring tissue (figure 21). 
 
2.4 Metatarsal assay 
The metatarsal assay is another ex vivo tissue-based angiogenesis assay [170]. This 
assay uses the metatarsal bones from embryonic E16.5 C57B6 wild-type mice. The 
dissected bones were plated onto 0.1% gelatin coated dishes and incubated for 2 days 
allowing the bones to settle. Any bones that failed to settle were disregarded as dead 
tissue. Desired treatments (PBS, 10ng/ml LBP, 20ng/ml LBP, 10ng/ml LBP + 1µg/ml 
LPS, 1µg/ml LPS) were then applied to the live samples for 7 days (fresh media + 
treatment every 3 days) before being stained with antibodies to detect PECAM-1, and 
imaging. This protocol has two advantages over the aortic ring assay; firstly the  
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Figure 18: Aortic Ring Assay Analysis. The top fluorescent image shows an aortic ring stained with 
isolectin B4 and imaged using Lecia epifluorescence microscope. The image was exported into ImageJ 
software and inverted. The freehand selection tool was used to trace the vessel sprouts and the mean 
pixel reading recorded (VESSEL+RING). The freehand selection tool was then used to trace around the 
ring and the mean pixel reading recorded (RING). The RING pixel reading was then subtracted from 
the VESSEL+RING value in order to give the isolated VESSEL value. The values were then averaged 
for each treatment and compared to control conditions. (Scale = 100µm). 
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Figure 19: Mouse Aortic Ring Angiogenesis Assay. Thoracic aortas were dissected from 2wk old 
C57B6 wild type mice. The tissue was placed onto collage-I gels and cultured in DMEM with 10% 
FCS. After 2 days incubation at 37oC 5% CO2 the rings were observed for fibroblast sprouting to 
indicate alive tissue. Fresh media + desired treatment was then added to the rings and they were 
reincubated. A) PBS Control B) 1µg/ml LPS C) 10ng/ml LBP D) 20ng/ml LBP E) 50ng/ml LBP F) 
10ng/ml LBP + 1µg/ml LPS G) 20ng/ml LBP + 1µg/ml LPS H) 50ng/ml LBP + 1µg/ml LPS I) 
100ng/ml VEGF J) 100ng/ml VEGF + 20ng/ml LBP K) 100ng/ml VEGF + 1µg/ml LPS. The treatment 
media was replenished every 2 days and after 8 days the tissue was fixed in 4% PFA, stained with 1:200 
Isolectin B4 (VECTOR) and imaged using a Lecia epiflourecent microscope. 6 mice were used for each 
experiment to give 10 rings per treatment (n=4). (Scale = 100µm). 
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Figure 20: Mouse Aortic Ring Angiogenesis Assay Analysis. Thoracic aortas were dissected from 
2wk old C57B6 wild type mice. The tissue was placed onto collage-I gels and cultured in DMEM with 
10% FCS. After 2 days incubation at 37oC 5% CO2 the rings were assessed for fibroblast sprouting to 
indicate alive tissue. Fresh media + desired treatment was then added to the rings and they were 
reincubated. A) PBS Control B) 1µg/ml LPS C) 10ng/ml LBP D) 20ng/ml LBP E) 50ng/ml LBP F) 
10ng/ml LBP + 1µg/ml LPS G) 20ng/ml LBP + 1µg/ml LPS H) 50ng/ml LBP + 1µg/ml LPS I) 
100ng/ml VEGF J) 100ng/ml VEGF + 20ng/ml LBP K) 100ng/ml VEGF + 1µg/ml LPS. The treatment 
media was replenished every 2 days and after 8 days the tissue was fixed in 4% PFA, stained with 1:200 
Isolectin B4 (VECTOR) and imaged using a Lecia epiflourecent microscope. The image was then 
exported into ImageJ. The pixel readings for the total sprouts observed with each treatment were then 
averaged and compared to control conditions. 6 mice were used for each experiment to give 10 rings per 
treatment (n=4). Student t-test was performed and the standard error of the mean calculated for each 
treatment p = <0.05 * <0.001 ** <0.0001 *** 
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Figure 21: LBP Stimulates Non-Vascular Cell Growth in the Mouse Aortic Ring. Aortic rings were 
treated with A) VEGF, and B) 20ng/ml LBP + VEGF, and stained for Isolectin B4. Images were 
obtained using a Leica epiflourescent microscope. In the presence of LBP (B1), but not VEGF (A1), we 
observed a large number of non-vascular cell types, marked with arrow heads (B1). (Scale = 100µm). 
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metatarsal tissue always sprouts even under basal conditions, unlike the aortic ring, 
which can sometimes produce no sprouts even with VEGF treatment. This makes the 
effects of treatments much easier to detect in the metatarsal assay. Secondly the 
images obtained from the metatarsal assay are suitable for IMARIS analysis (figure 
22). Imaris is a filament tracing software, which is able to trace vessel sprouts and 
analyse the volume, area and branch number in a network [171]. This makes the 
metatarsal assay analysis completely objective and removes any user experimental 
bias.  
 
The results (figures 23 and 24) supported the previous observations in the Matrigel 
and aortic ring assays with 10-20ng/ml LBP having a dose-dependent effect on 
vascular growth. Addition of LPS prevented this LBP-induced increase, and LPS 
treatment alone appeared to inhibit basal growth. As previously discussed (see 
Introduction 2) tip cells are indicative of sprouting angiogenesis [172], therefore 
metatarsal samples were magnified in an attempt to observe whether there was a 
change in the number of tip cells when treated with LBP (figure 25). Unfortunately the 
image resolution was not sufficient for detailed analysis but the images do suggest the 
presence of stereotypical tip cell filipodia projections in the control conditions. 
Furthermore the number of filipodia appeared to be elevated upon treatment with LBP 
alone, but with co-addition of LPS there were fewer filipodia and the cell tips 
appeared smooth.  
 
Data analysis showed that 20ng/ml LBP treatment was sufficient to increase overall 
vascular area as well as branch point number, and that LPS inhibited both of these 
effects. This suggests that LPS prevents LBP from inducing growth and remodelling 
of the vessel network (as is observed during intussusceptive angiogenesis, Introduction 
2). The Imaris software enables separation of the results into macro and microvessel 
denominations. Interestingly, this analysis showed that 20ng/ml LBP increased the 
area, length and the number of segments of macro but not microvessels (figures 26 and 
27). This could mean that a hypothetical LBP receptor is differentially expressed in the 
two vessel populations, or that only the larger vessels express the required proteins to 
exhibit an angiogenic response to LBP. 
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Figure 22: Mouse metatarsal angiogenesis assay with Imaris rendering. Magnified fluorescent 
metatarsal image was taken and inserted into the Imaris filament tracer software. The bone was set as a 
point of origin, macrovessels assessed by the programme and marked in white, microvessels assessed 
and marked as blue. (Scale = 100µm). 
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Figure 23: Mouse Metatarsal Angiogenesis Assay. Metatarsal bones were dissected from E16.5 
C57B6 wild type mice embryos. The bones were placed onto a 0.1% gelatin coated dish and cultured 
with EGM2. After 2 days incubation at 37oC 5% CO2 the bones were observed and any floating tissue 
disregarded. The settled bones then received desired treatment and were reincubated. A) PBS Control 
B) 10ng/ml LBP C) 20ng/ml LBP D) 10ng/ml LBP + 1µg/ml LPS E) 1µg/ml LPS. Every 3 days the 
treatment media was replenished and after 9 days the tissue was fixed in 4% PFA, stained with 1:200 
PeCAM-1 and imaged using a Leica epiflourecent microscope. 8 embryos were used for each 
experiment, yielding 4-7 bones per treatment (n=4). (Scale = 100µm). 
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Figure 24: Mouse Metatarsal Angiogenesis Assay Total Area and Branching Analysis. Metatarsal 
bones were dissected from E16.5 C57B6 wild type mice embryos. The bones were placed onto a 0.1% 
gelatin coated dish and cultured in EGM2. After 2 days incubation at 37oC 5% CO2 the bones were 
observed and floating samples disregarded. The settled bones then received desired treatment and were 
reincubated. A) PBS Control B) 10ng/ml LBP C) 20ng/ml LBP D) 10ng/ml LBP + 1µg/ml LPS E) 
1µg/ml LPS. Every 3 days the treatment media was replenished and after 9 days the tissue was fixed in 
4% PFA, stained with 1:200 PECAM-1 and imaged using a Lecia epiflourecent microscope. Images 
were exported into Imaris for analysis.  8 embryos were used for each experiment, yielding 4-7 bones 
per treatment. Student t-test was performed and the standard error of the mean calculated for each 
treatment p = <0.05 * <0.001 ** <0.0001 *** (n=4). 
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Figure 25: Mouse Metatarsal Tip Cell Analysis. Metatarsal bones were dissected from E16.5 C57B6 
wild type mice embryos. The bones were placed onto a 0.1% gelatin coated dish and cultured in EGM2. 
After 2 days incubation at 37oC 5% CO2 the bones were observed and floating samples disregarded. The 
settled bones then received desired treatment and were reincubated. A) PBS Control B) 10ng/ml LBP 
C) 20ng/ml LBP D) 10ng/ml LBP + 1µg/ml LPS E) 1µg/ml LPS. Every 3 days the treatment media was 
replenished and after 9 days the tissue was fixed in 4% PFA, stained with 1:200 PECAM-1 and imaged 
using a Leica epiflourecent microscope. Magnification ability of the microscope proved inadequate to 
visualise the sprouting tip cells. (Scale = 20µm) 
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Figure 26: Mouse Metatarsal Angiogenesis Assay Area and Length Analysis. Metatarsal bones 
were dissected from E16.5 C57B6 wild type mice embryos. The bones were placed onto a 0.1% gelatin 
coated dish and cultured in EGM2. After 2 days incubation at 37oC 5% CO2 the bones were observed 
and floating samples disregarded. The settled bones then received desired treatment and were 
reincubated. A) PBS Control B) 10ng/ml LBP C) 20ng/ml LBP D) 10ng/ml LBP + 1µg/ml LPS E) 
1µg/ml LPS. Every 3 days the treatment media was replenished and after 9 days the tissue was fixed in 
4% PFA, stained with 1:200 PECAM-1 and imaged using a Leica epiflourecent microscope. Images 
were exported into Imaris for analysis.  8 embryos were used for each experiment, yielding 4-7 bones 
per treatment. Student t-test was performed and the standard error of the mean calculated for each 
treatment p = <0.05 * <0.001 ** <0.0001 *** (n=4). 
 
 
 
 93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Mouse Metatarsal Angiogenesis Assay Volume and Segment Analysis. Metatarsal bones 
were dissected from E16.5 C57B6 wild type mice embryos. The bones were placed onto a 0.1% gelatin 
coated dish and cultured in EGM2. After 2 days incubation at 37oC 5% CO2 the bones were observed 
and floating samples disregarded. The settled bones then received desired treatment and were 
reincubated. A) PBS Control B) 10ng/ml LBP C) 20ng/ml LBP D) 10ng/ml LBP + 1µg/ml LPS E) 
1µg/ml LPS. Every 3 days the treatment media was replenished and after 9 days the tissue was fixed in 
4% PFA, stained with 1:200 PECAM-1 and imaged using a Leica epiflourecent microscope. Images 
were exported into Imaris for analysis.  8 embryos were used for each experiment, yielding 4-7 bones 
per treatment. Student t-test was performed and the standard error of the mean calculated for each 
treatment p = <0.05 * <0.001 ** <0.0001 *** (n=4). 
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Overall, the Imaris analysis of the metatarsal samples suggested that in contrast to the 
Matrigel and aortic ring assay, 10ng/ml LBP did not significantly increase 
angigogenesis, however 20ng/ml LBP promoted a statistically significant increase in 
vascular growth although the effect was smaller than that observed in the aortic ring 
assay. There are many possible reasons for the differences in response magnitude in 
these two experimental models. For example they could be due to the different cell 
types present within each culture and the age of the tissue. The Matrigel assay contains 
only cultured HUVEC (human macrovascular endothelium) and the aortic ring has 
adult rodent microvascular endothelia with supporting cells (e.g. smooth muscle cells), 
whereas the metatarsal assay uses embryonic tissue with developing endothelia, 
fibroblasts and supportive osteoblast cells. If one assumes the existence of a receptor 
for LBP, it could be that the osteoblasts, or other supporting cells express this 
molecule, and that modulation of those cells by LBP indirectly contributes to 
endothelial cell growth. Another possibility could be that embryonic endothelia lack 
the necessary receptor(s) or signalling molecules needed for a full LBP response, or 
that the activity of other angiogenic signalling pathways in this tissue makes LBP 
signalling at least partly redundant.   
 
Staining the metatarsals with isolectin B4, PECAM1 and DAPI showed that alongside 
the expected PECAM1 positive vasculature there was a population of isolectin B4 
positive cells. These unidentified cells are present in basal conditions but appeared to 
decrease upon LPS treatment (figure 28), suggesting that LPS is somehow detrimental 
to these cells. 
 
2.5 Oxygen Induced Retinopathy (OIR) 
Oxygen induced retinopathy (OIR) is a well-established model for investigating 
angiogenesis and has been in use in mice since 1994 [173]. Neonatal mice are exposed 
to hyperoxic (75%) conditions, usually from P7-P12. This abundance of oxygen 
causes retinal vessels to restrict and immature vessels to regress. This regression 
results in central vaso-obliteration and a delayed development of the deeper plexus. At 
P12-17 the mice are returned to normal oxygen (21%) conditions, which is sensed as 
hypoxic by the hyperoxic central retina, resulting in growth factor induction and vessel 
sprouting [173-175]. We used the OIR model to induce pathologic  
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Figure 28: Non-Vascular Cell Types in the Mouse Metatarsal Assay. Metatarsals were treated as 
follows; A) Control, B) 10ng/ml LBP, C) 20ng/ml LBP, D) 10ng/ml LBP + 1µg/ml LPS, E) 1µg/ml 
LPS and stained with PECAM1 (red), isolectin B4 (green) and DAPI bisbenzimide (blue) and imaged 
using a Leica epiflourescent microscope. The middle and right hand panels show higher magnification 
images of the corresponding low power images on the left. In the presence of LBP we observed an 
increase in an unidentified isolectin B4 positive cell type. This cell type was much less evident in the 
presence of LPS. (Scale = 100µm). 
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angiogenesis in the mouse eye in order to find out how the changes in oxygen tension 
might affect LBP expression. Three C57B6 wild type mice were placed into the hyperoxic 
conditions until P12 when their eyes were removed, neuroretinas dissected, RNA isolated 
for cDNA synthesis and LBP expression analysed via q-PCR. At this stage the retina is 
oxygen-rich and there is little vascular growth. 
 
The other set of three mice were also kept in hyperoxic conditions until P12 when they 
were placed into normal (hypoxic perceived) oxygen conditions until P17 when their eyes 
were removed, neuroretinas dissected, RNA isolated for cDNA synthesis and LBP mRNA 
expression analysed via q-PCR, with normalisation to ß-actin expression. At P17 the retina 
is depleted of oxygen and there is a sudden burst in vascular growth, therefore an increase 
in LBP expression at this time point would be consistent with a role in vascular 
proliferation in vivo. This may also indicate that the LBP promoter could contain a hypoxic 
response element (e.g. HIF) as in the case for certain established growth factors, such as 
VEGF [176].  
 
The results showed that at P12 LBP expression was down regulated relative to ß-actin, 
whilst at P17 it was up regulated (figure 29). This pattern mirrored that of VEGF [177], 
and is similar to other known regulators of angiogenesis such PlGF [178] and provides 
correlative evidence of an angiogenic role for LBP in an in vivo model, that supports the 
findings described earlier using ex vivo tissue models.  
 
 
3. Chapter Discussion 
The picture that emerges from these studies is that LBP clearly has a biological activity 
independent of its established role as a partner for LPS. To elicit the effects observed in 
these experiments it must therefore be assumed that LBP either binds to a cell surface 
receptor on endothelial or associated cells, or that its binds to another soluble factor, which 
in turn associates with a cell receptor.  
 
The Matrigel assay is the simplest model of angiogenesis used here, and has the advantage 
that using solely HUVEC removes the complication of multicellular interactions and the 
inevitable interplay between different cell types and their signalling activities  
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Figure 29: q-PCR Anlalysis of LBP expression after Mouse Oxygen-Induced Retinopathy (OIR). 
Neonatal C57B6 mice p9-12 were maintained in hyperoxic (75%) conditions and then place into 
standard oxygen conditions (21%) at p12-17. The eyes were removed at either p12 immediately after 
hyperoxia or at p17 after 5 days in perceived hypoxic conditions. The RNA was isolated (quality 
checked using Thermodynamic Nanodrop), cDNA synthesised and q-PCR analysis performed. LBP 
expression was normalised to ß-actin, VEGF expression was normalised to GAPDH (Dr. Xiaomeng 
Wang) and a percentage in gene expression calculated via comparison to mice without OIR (set as 0% 
change). Student t-test was performed and the standard error of the mean calculated for each treatment p 
= <0.05 * <0.001 ** <0.0001 *** (n=3). 
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[166, 167], LBP was found to increase sprout and branch number as well as the 
number of closed loop formations. The observed vessel sprouting enhancement reveals 
that LBP is able to promote HUVEC proliferation. Branching and loops are an 
indication of vascular network complexity and so suggest that LBP does more then 
just promote endothelial cell growth. If we consider sprout formation to approximate 
to sprouting angiogenesis, and complexity to provide a model of intussusceptive 
angiogenesis the data suggest that LBP may either potentiate VEGF signalling, which 
is known to be required for both angiogenic processes [11, 25, 26], or it could be 
inducing alternate pathways more specific to the type of growth alteration observed. 
Alternatively, LBP may have an activity similar to that of other angiogenic growth 
factors.  
 
In the aortic ring assay there is little if any spontaneous sprouting in basal conditions 
so 50ng/ml VEGF is added as a supplement to provide a positive control. Surprisingly 
50ng/ml LBP induced the same level of vascular sprouting as VEGF. It could be 
suggested from this observation that in this assay LBP is as potent an angiogenic 
factor as VEGF. However, it may be that the aortic ring tissue is relatively rich in the 
hypothetical LBP receptors and that the comparatively modest VEGF response 
indicates low levels or inaccessibility of VEGFR2’. Interestingly, with treatment using 
20ng/ml LBP + VEGF we observed an additive growth effect, as well as the presence 
of other unidentified cell types. These cells did not stain with Iba or F4/80, suggesting 
that they are not macrophages (data not shown). Morphologically, the cells resemble 
dendritic cells, which are known to play a role in angiogenesis [178, 179] but further 
staining would be required to identify these cells and determine their role in the assay.  
There are several possible explanations LBP enhancing the vascular growth we 
observed with VEGF alone; LBP may induce vascular growth via an angiogenic 
signalling pathway distinct to that of VEGF, so when both pathways are active this 
leads to increased growth. A second possibility is that LBP induces VEGF or another 
angiogenic growth factor to stimulate vascular growth even further. Our observations 
in the VLDLR-/- mouse, in which a substantial increase in LBP expression occurred 
just prior to the burst in VEGF expression may support the latter suggestion. 
 
Imaris rendered images of the metatarsal assay suggest that LBP may influence larger 
vessel growth more than small vessels, however the assignment of vascular sprouts 
 99 
into macro and micro phenotypes by the filament tracer did not appear completely 
accurate with the programme often labelling the initial vessel sprout as a macro-vessel 
and the terminal peripheral sprouts as microvessels. It may be that the terminal sprouts 
are more microvascular in nature but when regarding the Imaris images it appears that 
the assignment of ‘micro’ appears to be more dependent on the position of the sprout 
as opposed to its morphology, that is to say that some of the initial sprouts appear just 
as thin as the terminal sprouts, but because they are located close to the metatarsal the 
programme labels them as macrovessels. However, if the Imaris assignments are 
correct, this might imply that the end micro-sprouts have not fully matured into vessel 
tubes and so may not express the requisite cell surface markers or hypothetical 
receptors necessary to elicit a response to LBP. It would be interesting to isolate RNA 
from samples taken from macro and micro sections to identify whether there are any 
differences in gene expression between the two Imaris designated vascular types.  
 
Interestingly, as in the aortic ring assay, we observed that LBP treatment correlated 
with an increase in an isolectin B4 positive, unidentified cell type. Whether these are 
the same cell type in both arrays and whether they play a role in vascular growth is not 
known, but LPS treatment (where we observe a decrease or inhibition of angiogenesis) 
appeared to decrease the number of these cells, which suggests that they could indeed 
contribute to angiogenesis.   
 
In each assay LBP significantly enhanced vessel formation when used alone, though 
with a dramatic inhibition of these effects upon coincident addition of LPS. In 
combination, LBP + LPS will almost certainly induce an inflammatory response 
(providing the target cells express the required CD14 and TLR4), which in itself did 
not appear to affect basal levels of vascular growth. This supports LBP-induced 
inflammation as not being inherently detrimental to endothelial cells and suggests that 
LBP is not required for basal/physiological levels of vascular growth. Indeed, the sole 
publication describing the LBP knock-out mouse reported the animals to be essentially 
normal, and made no mention of any vascular phenotype [174]. Independent LPS 
treatment appeared to inhibit vessel growth suggesting that LPS may be cytotoxic and 
supporting the idea that LBP functions as an LPS ‘catcher’, to prevent or protect 
against the possible cytotoxic effects of endotoxin. 
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The OIR model showed LBP expression to be down-regulated in hyperoxic conditions 
and up-regulated in hypoxic conditions, providing further indirect support for a role in 
pathogenic angiogenesis. Thus, consistent with VEGF, LBP expression in adult C57B6 
wild type was suppressed in hyperoxia, but elevated during hypoxia. 
 
Taken together, these three angiogenesis assays and one induced in vivo angiogenic 
model provide compelling evidence that LBP is able to induce vascular growth. These 
observations imply that LBP has a function, independent from LPS, and suggests that 
LBP possess a novel growth factor activity. However it is important to note that these 
assays do not identify whether it is LBP itself that drives the vascular effects, or 
whether LBP is in fact inducing another factor (e.g. VEGF) that then mediates the 
angiogenic effects observed. Either way, the data imply the existence of a receptor for 
LBP on endothelial cells, and initial attempts to identify this molecule form the next 
chapter.  
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Chapter Three  
Investigation of the LBP Signalling Mechanism 
 
 
1. Background  
The current view of LBP is that it functions only when bound to LPS. During bacterial 
infection LBP binds to LPS and then either presents the endotoxin to CD14, inducing 
TLR4 signalling, activating NF-kß and inducing an inflammatory response [112, 151]  
or it promotes lipoprotein clearance of LPS from the circulation [181, 182]. Indeed, 
this was verified by the sole publication describing the LBP knock-out mouse, in 
which, the animals were shown to avoid septic shock upon endotoxin infection [181]. 
However, the observation reported in previous chapters suggest that LBP is capable of 
inducing an angiogenic response, and q-PCR analysis showed that LBP is expressed in 
Müller cells. These observations suggest that HUVEC and Müller cells would be 
appropriate cell types in which to investigate LBP signalling. 
 
1.2. Aim 
The aim of work in this chapter was therefore to use biological and biochemical 
techniques to explore the cellular responses to LBP, and to attempt to identify a 
candidate LBP receptor. 
 
2. Results 
2.1 Investigating the angiogenic switch 
It has been shown that macrophages which are co-stimulated with LBP + LPS and an 
A2aR agonist (e.g. adenosine) undergo an alteration in intracellular signalling, 
switching off the normal LBP + LPS inflammatory response and instead inducing 
VEGF expression [136]. We wanted to investigate whether other cell types were able 
to make this signalling switch and whether LBP + adenosine, without LPS could still 
induce VEGF. 
 
HUVEC and Müller cells were plated onto 35mm2 culture dishes, and serum-starved 
overnight before being subjected to a variety of treatments (PBS control, 10ng/ml LBP 
+ 1µg/ml LPS, 10ng/ml LBP + adenosine, 1µg/ml LPS, 1µM adenosine or 1µM 
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adenosine + 1µg/ml LPS + 10ng/ml LBP) for 12h. Cells were then lysed and analysed 
for VEGF expression using q-PCR.  
 
The results of this one-off experiment showed a slight decrease in VEGF expression in 
HUVEC, and a small increase in Müller cells (figure 30). However as HUVEC are 
reported to express very low levels of VEGF [183] the decrease we observed  with all 
treatment is unlikely to be physiologically meaningful. Müller cell VEGF expression 
was affected by all treatments, suggesting that the responses are probably non-specific. 
Taken together, these result suggest that the angiogenic switch does not occur in 
HUVEC or Müller cells and that LBP + adenosine alone do not induce VEGF in these 
cell lines. However it was noted that the cells were starved for 12h prior to a 12h 
treatment so it could be that the stress caused by 24h serum deprivation altered their 
signalling abilities or that different time points would have led to different outcomes. 
 
2.2 LBP does not induce NF-kß signalling  
LBP is known to induce NF-kß signalling when bound to LPS [115, 126]. We 
hypothesised that if LBP has an angiogenic activity independent of LPS, then it would 
be unlikely to stimulate the classic NF-kß pathway when applied on its own. To test 
this we utilised two read-outs of the NF-kß signalling pathway, ikßα phosphorylation 
on serines 32 and 36 [177], and p65 nuclear shuttling. As previously discussed (see 
Introduction 6.2) ikßα sequesters the NF-kß transcriptional elements (e.g. p65) in the 
cytoplasm in an inactive state. Upon cell activation ikßα is phosphorylated, releasing 
these transcriptional elements to translocate into the nucleus and drive gene 
transcription [184]. Therefore, if we observed ikßα phosphorylation and p65 nuclear 
staining after the cells are treated with LBP, this would suggest that LBP acts on its 
own much in the same way as it does with LPS. 
 
Müller cells were plated onto 35mm2 tissue culture dishes and serum-starved 
overnight before being treated as followed (PBS control, 10ng/ml LBP, 1µg/ml LPS or 
10ng/ml LBP + 1µg/ml LPS) for 5min – 1h. The cells were then lysed and the samples 
resolved by SDS-PAGE with subsequent immunoblot detection of phosphorylated 
ikßα. The results showed (figure 31) that upon LBP + LPS treatment  
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Figure 30: Angiogenic Switch Investigation in HUVEC and Müller cells. HUVEC and Müller cells 
were seeded onto 35mm2 culture dishes and starved overnight before being treated with either PBS 
control, 10ng/ml LBP + 1µg/ml LPS, 10ng/ml LBP + 1µM adenosine, 1µg/ml LPS, 1µM adenosine or 
1µM adenosine + 1µg/ml LPS + 10ng/ml LBP for 12h. Cells were then lysed, RNA isolated and cDNA 
synthesised. VEGF expression was analysed using q-PCR and the fold change in VEGF expression 
calculated by normalisation to cell matched ß-actin expression levels. (n=1) 
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ikßα was phosphorylated but that there was no response to LBP treatment alone. Thus, 
LBP treatment alone does not appear to activate NF-kß in Müller cells. 
 
Next, HUVEC and Müller cells were plated onto 35mm2 tissue culture dishes and 
starved overnight before being treated with the desired treatment (PBS control, 
10ng/ml LBP or 10ng/ml LBP + 1µg/ml LPS) for 15 min, fixed with PFA, 
permeabilised with Triton-X 100 and stained with antibodies to detect p65. The results 
showed that again, whilst LBP + LPS treatment was sufficient to induce p65 nuclear 
translocation, LBP treatment alone was not (figures 32 and 33). These observations 
support the ikßα phosphorylation data and provide evidence that LBP is unable to 
induce NF-kß signalling independent of LPS. 
 
 
 
 
 
 
 
 
Figure 31: ikßα phosphorylation observed in Müller cells. MIO-M1 Müller cells were treated with 
10ng/ml LBP, 1µg/ml LPS or 10ng/ml LBP + 1µg/ml LPS for 5min – 1h, lysed and samples ran on a 
10% SDS gel before being immunoblotted with an antibody to detect serine 32/36 phosphorylated ikßα.  
Bands were visualised using ECL. The imaged gel was inverted in ImageJ. The line depicts the 
phospho- ikßα protein band. 
 
 
2.3 LBP induces a phosphotyrosine response  
Having established that LBP alone did not elicit the same response as LBP + LPS, we 
next used two non-specific read-outs of cell activation, namely ERK phosphorylation 
and global tyrosine phosphorylation, to gain insight into the cellular responses to LBP.  
 
Two immortalised rat brain endothelial cell lines, GPNT [186] and RBE4 [187], and 
Müller cells were plated onto 35mm2 tissue culture dishes and starved overnight 
before being treated with either PBS (control), 10ng/ml LBP or 10ng/ml LBP + 
1µg/ml LPS for 0-8h. The cells were then lysed and the samples resolved by SDS-
PAGE prior to western blotting and immuno-detection of phosphotyrosine. The results 
showed that LBP was able to induce protein tyrosine phosphorylation in all of  
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Figure 32: Nuclear Translocation of p65 in HUVEC. HUVEC (passage 2) were seeded onto 35mm2 
culture dishes, cultured in EGM2 and left to reach 70% confluence before being serum starved 
overnight and treated with either A) PBS control, B) 10ng/ml LBP or C) 10ng/ml LBP + 1µg/ml LPS 
for 15min. Cells were then fixed in 4% PFA and incubated with an antibody to detect p65 (Santa Cruz 
C20, 0.2µg/ml) and Dapi bisbenzimide (1µg/ml). Cells were then imaged using a Leica epifluorescent 
microscope. A1-C1 are magnifications with arrows showing the cell nucleus. (n=3) (Scale = 40µm, 
zoom = 5µm). 
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Figure 33: Nuclear Translocation of p65 in MIO-M1 Cells. MIO-M1 Müller cells were seeded onto 
35mm2 culture dishes, cultured in DMEM with 10% FCS and left to reach 70% confluence before being 
serum starved overnight and treated with either A) PBS control, B) 10ng/ml LBP or C) 10ng/ml LBP + 
1µg/ml LPS for 15min. Cells were then fixed in 4% PFA and incubated with an antibody to detect p65 
(Santa Cruz C20, 0.2µg/ml) and Dapi bisbenzimide (1µg/ml). Cells were then imaged using a Leica 
epifluorescent microscope. A1-C1 are magnifications with arrows showing the cell nucleus. (n=3) 
(Scale = 40µm, zoom = 5µm). 
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the cell lines tested (see figures 34, 35 and 36). There was some variation in the 
kinetics of the response, with GPNT taking the longest time to respond, however we 
noted that two phospho-bands of 60kDa and 150kDa appeared to be most intense in all 
three cell lines, suggesting that these two proteins could be important for LBP signal 
transduction. 
 
In order to identify some of the tyrosine phosphorylated proteins we scaled up the 
process for mass spectroscopy. Müller cells were treated with either PBS or 10ng/ml 
LBP for 30min and then lysed in 250µl 2x lysis buffer (no SDS). The lysates were first 
incubated with empty agarose beads in order to clear the samples of sticky protein 
aggregates. They were then incubated with anti-phosphotyrosine agarose beads before 
being washed repeatedly to remove any non-specific bound protein. The samples were 
then heated to denature the antibody, therefore dissociating the proteins from the 
beads, before being resolved by 10% SDS-PAGE and visualised with Coomassie blue 
staining (figure 37). The 150-140kDa and 60kDa bands together with a few other 
prominent bands were then cut out of the gel, placed into Eppendorf tubes and 
despatched for Mass-Spectroscopy peptide fingerprint sequencing by Alphalyse 
pick’n’post (figure 38). Alphalyse analysis was unable to obtain sequence from the 
140-150kDa protein band but did reveal that the 60kDa protein was vimentin and 
some other protein bands found to change upon LBP treatment were Myosin-9, 
heterogeneous nuclear ribonucleoprotein A1 (HNRPA1) and heterogeneous nuclear 
ribonucleoprotein U (hnRNPU). 
 
The majority of LBP + LPS signalling occurs via TLR4 and has been shown to 
stimulate protein tyrosine phosphorylation [118], therefore to be sure that what we 
observed with LBP was different from LBP + LPS treatment, we compared the 
phosphotyrosine response of HUVEC treated with either LBP alone or LBP + LPS. 
The results showed that whilst LBP alone was able to induce tyrosine phosphorylation 
of bands at 150kDa and 60kDa within 30 min, LBP + LPS was not (figure 39). This 
shows that the phosphotyrosine responses observed in HUVEC and the other cell lines 
are specific to LBP activity alone. These observations also reaffirm that our 
experimental systems are absent of LPS, and reinforce the idea that LBP signalling is 
distinct from signalling by LBP + LPS. 
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Figure 34: LBP Stimulates Tyrosine Phosphorylation in MIO-M1 Cells. MIO-M1 Müller cells were 
seeded onto 35mm2 culture dishes cultured in DMEM with 10% FCS and left to reach 70% confluence 
before being serum starved overnight and treated with either PBS control or 10ng/ml LBP for 5min – 
8h. The cells were then lysed in 200µl 2x lysis buffer and boiled at 95oC for 5 min. 25µl of each sample 
was resolved via SDS-PAGE, transferred onto nitrocellulose membrane, blocked and incubated 
overnight at 4oC with 4G10 anti-phosphotyrosine antibody (Millipore 1:3000). The membranes were 
then developed and films analysed for an increase in phosphotyrosine. Membranes were then stripped 
and reblocked before being reincubated with an antibody to detect actin (Millipore 1:5000) as a protein 
loading control.  The film images were exported to ImageJ and inverted. A box was traced around the 
protein band of interest and a mean pixel reading recorded. The phosphotyrosine reading was then 
divided by the time-matched actin value. Average values for total phosphotyrosine, 150kDa protein 
band and 60kDa protein band was calculated from 3 experiment repeats. Student t-test was performed 
and standard error of the mean calculated (n=3) p = <0.05 * <0.001 ** <0.0001 ***  
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Figure 35: LBP Stimulates Tyrosine Phosphorylation in RBE4 Cells. RBE4 cells were seeded onto 
35mm2 culture dishes, cultured in 1:1 alpha-MEM, F-10 with 10% FCS and left to reach 70% 
confluence before being serum starved overnight and treated with either PBS control or 10ng/ml LBP 
for 5min – 8h. The cells were then lysed in 200µl 2x lysis buffer and boiled at 95oC for 5 min. 25µl of 
each sample was resolved via SDS-PAGE, transferred onto nitrocellulose membrane, blocked and 
incubated overnight at 4oC with 4G10 anti-phosphotyrosine antibody (Millipore 1:3000). The 
membranes were then developed and films analysed for an increase in phosphotyrosine. Membranes 
were then stripped and reblocked before being reincubated with an antibody to detect actin (Millipore 
1:5000) as a protein loading control.  The film images were exported to ImageJ and inverted. A box was 
traced around the protein band of interest and a mean pixel reading recorded. The phosphotyrosine 
reading was then divided by the time-matched actin value. Average values for total phosphotyrosine, 
150kDa protein band and 60kDa protein band was calculated from 3 experiment repeats. Student t-test 
was performed and standard error of the mean calculated (n=3) p = <0.05 * <0.001 ** <0.0001  
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Figure 36: LBP Stimulates Tyrosine Phosphorylation in GPNT Cells. GPNT cells were seeded onto 
35mm2 culture dishes, cultured in 1:1 alpha-MEM, F-10 with 10% FCS and left to reach 70% 
confluence before being serum starved overnight and treated with either PBS control or 10ng/ml LBP 
for 5min – 8h. The cells were then lysed in 200µl 2x lysis buffer and boiled at 95oC for 5 min. 25µl of 
each sample was resolved via SDS-PAGE, transferred onto nitrocellulose membrane, blocked and 
incubated overnight at 4oC with 4G10 anti-phosphotyrosine antibody (Millipore 1:3000). The 
membranes were then developed and films analysed for an increase in phosphotyrosine. Membranes 
were then stripped and reblocked before being reincubated with an antibody to detect actin (Millipore 
1:5000) as a protein loading control.  The film images were exported to ImageJ and inverted. A box was 
traced around the protein band of interest and a mean pixel reading recorded. The phosphotyrosine 
reading was then divided by the time-matched actin value. Average values for total phosphotyrosine, 
150kDa protein band and 60kDa protein band was calculated from 3 experiment repeats. Student t-test 
was performed and standard error of the mean calculated (n=3) p = <0.05 * <0.001 ** <0.0001 ***  
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Figure 37: Phosphotyrosine Pull Down of MIO-M1 cells treated with LBP. MIO-M1 Müller cells 
were seeded onto 35mm2 culture dishes, immersed in DMEM with 10% FCS and left to reach 70% 
confluence before being serum starved overnight and treated with either PBS control or 10ng/ml LBP 
for 30min. The cells were then lysed in 50µl 2x lysis buffer (-SDS) and incubated with agarose beads on 
a rotator for 1h before being washed in lysis buffer (-SDS) and incubated with anti-phospotyrosine 
agarose beads at 4oC on a rotator for 2h. The beads were then washed extensively in ice cold PBS 
before being boiled at 95oC for 5 min. The entire sample was resolved via SDS-PAGE and the gel 
incubated in comassie blue for 30min before being incubated in destain solution on a shaking plate >8h 
with frequent solution changes. The gel was then observed (n=2) and any protein bands of interest 
isolated to be sent to Alphalyse Pick’n’Post for peptide fingerprint mass spectroscopy sequencing.  
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Figure 38: Phosphotyrosine Pull Down Protein Band Sequence Matches. The proteins isolated in 
figure 35 were subjected to peptide fingerprint mass spectroscopy, and identified as Myosin-9, 
hnRNPU, Vimentin and HNRAP1. The primary human amino-acid sequences are given for each 
protein, with the matching peptides highlighted in bold and underlined in each case.  
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Figure 39: HUVEC protein tyrosine phosphorylation post-LBP treatment. HUVEC (passage 3) 
were seeded onto 35mm2 culture dishes, EGM2 and left to reach 70% confluence before being serum 
starved overnight and treated with either PBS control, 10ng/ml LBP  or 10ng/ml LBP + 1µg/ml LPS for 
5min – 1h. The cells were then lysed in 200µl 2x lysis buffer and boiled at 95oC for 5 min. 25µl of each 
sample was resolved via SDS-PAGE, transferred onto nitrocellulose membrane, blocked and incubated 
overnight at 4oC with 4G10 anti-phosphotyrosine antibody (Millipore 1:3000). The membranes were 
then developed and films analysed for an increase in phosphotyrosine. Membranes were then stripped 
and reblocked before being reincubated with an antibody to detect actin (Millipore 1:5000) to use as a 
protein loading control.  The film images were exported to ImageJ and inverted (n=2). 
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2.4 LBP induces ERK phosphorylation  
Previous angiogenesis assays demonstrated that LBP increases vascular growth, and 
data in the previous section show that LBP promotes phosphotyrosine signalling 
independently of LPS, therefore we decided to focus our attention on signalling 
pathways that could influence cell proliferation and survival. As mentioned earlier 
(See Introduction 6.4) the ERKs are a family of serine/threonine kinases that are 
phosphorylated during cell activation and have roles in a wide range of cellular 
processes including survival, cell cycle and proliferation [139, 142]. We wanted to 
investigate whether LBP was able to induce ERK phosphorylation as this would be 
consistent with the angiogenic activity of LBP reported earlier.  
 
HUVEC and Müller cells were plated onto 35mm2 tissue culture dishes and starved 
overnight before being treated with PBS (control), 10ng/ml LBP or 10ng/ml LBP + 
1µg/ml LPS for 5min – 1h. Cells were then lysed and the samples resolved by SDS-
PAGE, followed by western transfer, and then immunoblot detection of phospho-
ERK. The results showed that LBP was able to induce a phospho-ERK response in 
both HUVEC and Müller cells within 5 min (figure 40). The effect appeared stronger 
but transient in the Müller cells with basal levels of phospho-ERK re-established 30 
min after treatment. HUVEC showed a smaller but prolonged response, with phospho-
ERK still apparent 1h after treatment. This suggests some differences between the cell 
lines, consistent with the variations we had previously observed in phosphotyrosine 
responses. When the Müller cells were treated with LBP + LPS there appeared to be 
some phospho-ERK induction but this was not as marked as when cells were treated 
with LBP alone. HUVEC did not exhibit a phospho-ERK response when treated with 
LBP + LPS, indicating that their phospho-ERK response was specific to LBP. 
 
2.5 Identification of a candidate LBP receptor 
During the Matrigel assay experiments we had observed that once the HUVEC were 
beyond passage 10 they stopped being responsive to LBP treatment (figure 41). It is 
well known that as primary cells are passaged they alter their patterns of gene 
expression. This suggested to us that >p10 HUVEC no longer express the hypothetical 
‘LBP receptor’ required for signal activation. As Müller cells had been  
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Figure 40: MIO-M1 and HUVEC phosphorylated ERK response post-LBP +/- LPS Treatment. 
MIO-M1 Müller cells and HUVEC (passage 3) were seeded onto 35mm2 culture dishes and immersed in 
DMEM 10% FCS or EGM2 respectively. The cells were left to reach 70% confluence before being 
serum starved overnight and treated with either PBS control, 10ng/ml LBP  or 10ng/ml LBP + 1µg/ml 
LPS for 5min – 1h. The cells were then lysed in 200µl 2x lysis buffer and boiled at 95oC for 5 min. 25µl 
of each sample was resolved via SDS-PAGE, transferred onto nitrocellulose membrane, blocked and 
incubated overnight at 4oC with an anti phospho-ERK antibody (Cell signalling 1:3000). The 
membranes were then developed and films analysed for an increase in phospho-ERK. Membranes were 
then stripped and reblocked before being reincubated with an antibody to detect ERK (Millipore 
1:5000) to use as a protein loading control.  The film images were exported to ImageJ and inverted 
(n=2). 
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Figure 41: HUVEC (passage 10) Matrigel Angiogenesis Assay. HUVEC were seeded onto growth 
factor reduced Matrigel (BD) at 2x105/ml cell density. Treatments were then added (PBS control, 
10ng/ml LBP, 10ng/ml LBP + 1µg/ml LPS or 1µg/ml LPS and the gels incubated overnight at 37oC 5% 
CO2. The gels were imaged using a Lecia epifluorescence microscope under brightfield conditions. 
Sprouts, branch points and closed loops were counted manually. Student’s t-test was performed and 
standard error of the mean calculated p = <0.05 * <0.001 ** <0.0001 ***  (n=3). 
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found to respond to LBP regardless of passage number we decided to compare old and 
young HUVEC to Müller cells with the assumption that commonalities could lead to 
the identification of a candidate LBP receptor. In an attempt to focus the search we 
decided to test three receptor families. These were the TLRs, since LBP + LPS signal 
via TLR4 [121], and the glypican and syndecan families because BPI, the protein with 
the highest sequence and structural homology to LBP, has been reported to signal 
through glypican-4 [112, 124].  
 
RNA was isolated from old (passage 13) and young (passage 2) HUVEC and Müller 
cells. cDNA was synthesised and RT-PCR was used to check for TLR, glypican and 
syndecan expression. The results showed  (figure 42) that the old and young HUVEC 
both express TLR4, suggesting that LBP does not elicit angiogenic responses via the 
receptor it binds with LPS. When passaged the HUVEC lose expression of TLR1, 
which would be consistent with a candidate LBP receptor, however Müller cells 
showed no TLR1 expression suggesting this is not the case. Old and young HUVEC 
did not express any of the glypicans unlike Müller cells, which express glypican-5. 
Interestingly the early passage HUVEC expressed one member of the syndecan 
family, namely syndecan-2, which was also expressed at high levels in the Müller cells 
and was lost in passage 13 HUVEC (figure 43). Therefore, among the three protein 
families, this singled out syndecan-2 as the sole candidate LBP receptor. Interestingly, 
syndecan-2 is the only member of these receptor families reported to play a role in 
angiogenesis, through potentiation of VEGF-A signalling [188].  
 
2.6 siRNA knock down of syndecan-2 inhibits the LBP phospho-ERK response 
Having identified syndecan-2 as a candidate LBP receptor the aim of the next 
experiment was to knock-down syndecan-2 expression and observe any changes in the 
LBP-induced phospho-ERK response. Ideally HUVEC would have been used for this 
experiment but due to time constraints and a requirement for an adenovirus-induced 
knockdown the protocol was instead attempted in Müller cells using oligofectamine. 
However, after numerous attempts at optimisation an effective knock-down was not 
achieved, and we were forced to consider other options. We found that Hela cells 
express syndecan-2, have a phospho-ERK response to LBP treatment and can achieve 
a reasonable syndecan-2 RNA knock-down within 2 days (figure 44). Therefore Hela 
cells were used for testing the requirement of syndecan-2  
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Figure 42: HUVEC and MIO-M1 Toll-Like Receptor RT-PCR Analysis. HUVEC (passage 2 and 
13) and MIO-M1 Müller cells were seeded onto 35mm2 culture dishes and immersed in EGM2 or 
DMEM 10% FCS respectively. RNA was isolated, cDNA synthesised and RT-PCR analysis performed 
to analyse TLR receptor expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: HUVEC and MIO-M1 Glypican and Syndecan RT-PCR Analysis. HUVEC (passage 2 
and 13) and MIO-M1 Müller cells were seeded onto 35mm2 culture dishes and immersed in EGM2 or 
DMEM 10% FCS respectively. RNA was isolated, cDNA synthesised and RT-PCR analysis performed 
to analyse GPC and SDC receptor expression. 
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Figure 44: Hela Syndecan-2 Knock Down RT-PCR Analysis. Hela cells were transfected with 
human SDC2 siRNA using oligofectamine reagent. Ambion and Santa Cruz siRNA’s were tested for 
efficiency. Ambion siRNA was supplied as three separate probes, each probe was tested alone (1, 2 and 
3), in pair (1/2, 1/3 and 2/3) and in a pool together (1/2/3). They were delivered in 2x 100pmol 
transfections with cells harvested 2 days afterwards. Santa Cruz siRNA was delivered as a ready mixed 
pool of three probes and was given in a low dose of 2x 50pmol or high dose of 2x 100pmol 
transfections with cells harvested 2 days afterwards. RNA was isolated and quality checked using 
Thermodynamic Nanodrop. cDNA was synthesised and RT-PCR techniques used to analysis SDC2 
expression.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45: Phospho-ERK Response in Hela Cells Depleted in Syndecan-2. Hela cells were 
transfected with human SDC2 siRNA (50pmol Santa Cruz) using oligofectamine reagent to knock down 
SDC2 protein. The cells were then starved for 36h before being treated with PBS control, 10ng/ml LBP, 
10ng/ml LBP + 1µg/ml LPS, 1µg/ml LPS or 50ng/ml LBP for 30min. The cells were lysed in 200µl 2x 
lysis buffer and resolved by 10% SDS-PAGE. Proteins were then transferred to a nitrocellulose 
membrane and the membrane immunoblotted for pERK. The blots were developed and imaged on film 
before being stripped and reprobed for total ERK protein. Gel images were exported to ImageJ and 
inverted (n=1). 
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for the LBP phospho-ERK response.  
 
Hela cells were plated onto 24-well plate culture dishes at approximately 40% 
confluency and transfected with 100pmol syndecan-2 siRNA (Ambion) or control 
scrambled siRNA (Sigma) for 8h, the cells were then washed twice in fresh media and 
left overnight. The following morning the cells were trypsinized and split 1:2 before 
being transfected as before for a further 8h. The cells were then washed again in media 
and left overnight. On day three the cells were washed once and placed into fresh 
media for 24h. On day four the cells were washed and starved for 48h before being 
treated with 10-50ng/ml LBP, 10ng/ml LBP + 1µg/ml LPS or 1µg/ml LPS for 30min. 
The cells were then lysed and the samples resolved using SDS-PAGE, followed by 
immunoblot detection of phospho-ERK. Preliminary results showed that 10-50ng/ml 
LBP treatment was able to induce a phospho-ERK response in scrambled control 
siRNA treated Hela cells but not in the syndecan-2 knocked down cells (figure 45). In 
control Hela cells LBP+LPS and LPS alone were able to induce phospho-ERK, 
knocking down syndecan-2 did not appear to affect this response. These data support 
the idea that syndecan-2 is required for the LBP-independent effects, and suggest that 
in Hela cells syndecan-2 mediates the phospho-ERK response induced by LBP, but 
not that by LBP + LPS or LPS alone.  
 
2.7 LBP induces VEGF in Müller cells and TGFß1 in HUVEC 
The angiogenesis assays had shown that LBP treatment enhanced vascular growth, 
with preliminary in vitro results suggesting LBP may mediate this effect through 
syndecan-2 and ERK signalling. VEGF and TGFß1 are potent growth factors able to 
induce endothelial proliferation [15, 111]. Other groups have shown syndecan-2 can 
potentiate VEGF-A [188] and TGFß1 [189] signalling so we next decided to 
investigate whether LBP was able to induce either, or both, of these growth factors in 
HUVEC or Müller cells. 
 
HUVEC and Müller cells were plated onto 35mm2 tissue culture dishes and starved 
overnight before being treated for 2-6h with either PBS or 10ng/ml LBP. Cells were 
then lysed, RNA isolated, cDNA synthesised and VEGF / TGFß1 expression analysed 
using q-PCR. Fold changes were calculated via normalisation to cell matched ß-actin 
expression levels. The results showed that after 2h LBP treatment  
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Figure 47: LBP induces TGFß1 and VEGF in a Cell Specific Manner. HUVEC (P2) and Müller 
cells were seeded onto 35mm2 culture dishes and starved overnight before being treated with either PBS 
control or 10ng/ml LBP for 2-6h. Cells were then lysed, RNA isolated and cDNA synthesised. VEGF 
and TGFß1 expression was anaylsed using q-PCR and the fold change in gene expression was 
calculated by normalisation to cell matched ß-actin expression levels. (n=1). 
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HUVEC expressed >3x more TGFß1 but exhibited no increase in VEGF expression, 
whilst after 2-6h of LBP treatment, Müller cells expressed >3x more VEGF but 
exhibited no increase in the TGFß1 expression (figure 47). This suggests that LBP is 
able to modulate the expression of other angiogenic growth factors in a cell-type 
specific manner.  
 
3. Chapter Discussion 
There are two branches to the NF-kß signalling pathway, the canonical and non-
canonical [121]. LBP + LPS signalling is known to activate the canonical pathway, 
inducing ikßα phosphorylation and p65 nuclear translocation [116]. Our experiments 
here indicate that LBP treatment alone is not sufficient to induce NF-kß. However it is 
important to note that these experiments examined cells at pre-determined timepoints 
(5min-1h) and we cannot completely rule out the possibility that LBP may induce ikßα 
phosphorylation and p65 nuclear shuttling outside of this time frame. Also, p65 is not 
the only activator of NF-kß gene transcription, c-Rel, RelB and p50 [122, 125] could 
also be activated to enter the nucleus and although LBP + LPS usually functions via 
p65 it could be that LBP alone induces a related factor.  
 
LBP was shown to be able to induce phosphotyrosine responses in three endothelial 
cell lines (GPNT, RBE4 and HUVEC) and MIO-M1 Müller cells with two protein 
bands of 150kDa and 60kDa appearing to increase the most. Initially we attempted to 
identify the 60kDa band using the ‘educated guess’ approach. Several members of the 
Src family of tyrosine kinases have a molecular weight of approximately 60kDa, and 
these are commonly activated by tyrosine phosphorylation in multiple cell signalling 
pathways [190, 191]. However, probing blots with various phospho-specific Src 
antibodies led us to conclude this protein was probably not a member of this kinase 
family (data not shown).  
 
In order to unequivocally identify the unknown protein bands we therefore performed 
mass spectroscopic analysis from a phosphotyrosine pull down using control vs. LBP 
stimulated Müller cell lysates. Five protein bands were selected for identification. No 
sequencing results were obtained for the 150kDa band, the 35kDa band was identified 
as myosin-9, which is a non-muscle myosin believed to associate with ALK in 
anaplastic large cell lymphoma [192]. A further two bands were identified as 
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heterogeneous nuclear ribonucleoprotein A1 (HNRPA1) and heterogeneous nuclear 
ribonucleoprotein U (hnRNPU), both of which bind to RNA to influence pre-mRNA 
processing and transport from the nucleus [193, 194]. Interestingly, the 60kDa protein 
was identified as vimentin.  
 
Vimentin is an intermediate filament protein, which has been found to be important for 
cell integrity. It generally associates with the endoplasmic reticulum, nucleus and 
mitochondria and functions to anchor organelles in the cytoplasm [195]. It has been 
observed that an increase in vimentin serine phosphorylation is linked to epithelial 
cells taking on a mesenchymal state [196] and that cell surface expression of vimentin 
increases angiogenesis [197]. Phosphorylation of vimentin has also been reported to 
increase during cell mitosis and motility [198] which would be consistent with the 
observations that LBP enhances vessel growth in the angiogenesis assays. However, 
most reports of vimentin phosphorylation are in regard to serine phosphorylation, and 
to the best of our knowledge our findings here are the first identification of tyrosine 
phosphorylation of vimentin.  
 
ERK is activated through phosphorylation by the upstream MAP kinases, MEK1/2 and 
has a long established role in regulating cell survival, differentiation and proliferation 
though induction of growth factors, such as VEGF [139, 199-202]. Here we show that 
LBP can induce phospho-ERK in HUVEC and Müller cells, which supports the 
increased growth we observed in the angiogenesis assays. It is interesting that LBP + 
LPS appeared to initially increase phospho-ERK in Müller cells and then inhibit it, this 
could suggest some kind of negative feedback loop for the phospho-ERK activation 
caused by LBP + LPS.  
 
RT-PCR comparisons of old (passage 13) LBP unresponsive and young (passage 2) 
LBP-sensitive HUVEC showed that upon multiple passages the cells down-regulate 
expression of a heparan sulphate proteoglycan (HSPG) syndecan-2. Syndecan-2 
belongs to a small HSPG sub-family, along with three further syndecans and six 
glypicans. Syndecans are type 1 transmembrane proteoglycans, which can vary greatly 
in size depending on their side chain attachments [202, 203]. They all share a 
conserved core protein and a short cytoplasmic tail and it is the divergence of their 
side chains that determines the ligands with which they can interact [203-205]. They 
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are present on the cell surface usually as homodimers, occasionally as multimers  
[203-205]. Syndecan-2 has been shown to have altered expression in cancer and to be 
involved in cell proliferation and migration [206-209]. Interestingly syndecan-2 is the 
only member of the syndecan family to be linked to vascular behaviour, with some 
groups reporting that it is vital for sprouting angiogenesis [210, 211]. Moreover zebra 
fish studies have found syndecan-2 to interact directly with VEGF-A and have shown 
that VEGF165 induced angiogenic sprouting is compromised in syndecan-2 mutants 
[189]. Unfortunately, syndecan-2 is the only member of this HSPG family not to have 
been genetically targeted in mice, therefore we had to use siRNA to investigate the 
potential role of syndecan-2 as a receptor for LBP. siRNA knockdown in Hela cells 
showed that syndecan-2 is indeed required for LBP induction of phospho-ERK, 
supporting the notion that LBP promotes angiogenesis via syndecan-2. However these 
are preliminary data in need of further validation. In particular we have only been able 
to establish a knockdown of SDC2 at the RNA level due to the technical challenges of 
western blotting for the protein. It would be important to confirm that the syndecan-2 
protein expression is correspondingly diminished by the knockdown protocol. Also, 
despite 48h of starvation the Hela cells still exhibited a relatively high basal level of 
phospho-ERK, so although it was still possible to observe an increase in phospho-
ERK with LBP treatment, ideally one would want a cell line with a lower basal level 
of ERK phosphorylation in future experiments.  
 
q-PCR analysis of gene expression in HUVEC and Müller cells post LBP treatment 
showed that LBP induces alternate growth factors in the different cell lines (TGFß1 in 
HUVEC and VEGF in Müller cells). This is interesting as both are angiogenic factors, 
and shows that LBP may stimulate cell type-specific gene expression. Futhermore, 
induction of TGFß1 activity by LBP may explain why we observed enhanced vascular 
sprouting with LBP + VEGF treatments in the aortic ring angiogenesis assay (Results 
chapter 2 figures, 19 and 20).  
 
Previously it was thought LBP only had signalling effects when bound to LPS, 
however we have identified a novel function for this protein. LBP can in fact induce 
phosphotyrosine responses in Müller, HUVEC, GPNT and RBE4 cells and can induce 
phosphoERK responses in Müller, HUVEC and Hela cells. The experiments show that 
LBP-induced signalling is different from that of LBP + LPS in that LBP does not 
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appear to activate the NF-kß p65 regulated pathway. We have also shown, by 
inference, that LBP does not signal via TLR4, and in syndecan-2 we have identified a 
candidate receptor for LBP already implicated in angiogenesis.  
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Summary and Conclusions 
 
 
Previous work investigating LBP has identified it as being an important protein of the 
innate immune system. Primarily synthesised and secreted by macrophages, LBP 
functions to bind to circulating LPS, which is shed from the cell walls of gram-
negative bacteria such as E. coli. Once bound, LBP-LPS can initiate TLR4 signalling 
to induce NF-kß transcription, cytokine production and an inflammatory response. The 
CD14 antigen has been reported to enhance the efficiency of LBP-LPS signalling. 
There are two types of CD14, membrane bound (mCD14, which is expressed on cells 
such as endothelial cells) and secretory (sCD14, which allows non-CD14 expressing 
cells to respond to LBP-LPS) [118, 122, 123, 212].  
 
Through microarray analysis our group identified LBP as being increased in mouse 
models that display abnormal retinal vasculature. Further characterisation of the 
VLDLR-/- mouse showed LBP to be up-regulated prior to the onset of vascular 
abnormalities and an associated increase in VEGF. This is important because a gene 
that is identified as being up-regulated in a microarray may be so either as a 
consequence of vascular remodelling / angiogenesis or because it has a causative pro-
angiogenic activity.   
 
These observations suggested a possible functional link between VEGF and LBP, this 
was an unexpected result but the links between immunity and angiogenesis have been 
implicated in many investigations, with LBP previously reported to have a role in the 
‘angiogenic switch’ [136]. For these reasons LBP was judged to be a good candidate 
for further investigation.  
 
Macrophages co-stimulated with a TLR agonist and an adenosine A2a receptor agonist 
(such as adenosine) have been found to switch off inflammatory signalling and instead 
activate VEGF production [136]. Although the retina is an immune-privileged tissue it 
does contain some resident macrophages [213], and clearly these could be a source of 
LBP in the context of vascular growth. However the microarray study was performed 
on isolated retinal vessels, which we assume to be essentially free of macrophages, so 
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we decided to investigate whether LBP could activate the angiogenic switch in 
endothelial cells. In our initial studies using cultured endothelial cell lines (HUVEC, 
GPNT and RBE4) we not only found that they failed to activate VEGF transcription 
upon LBP + adenosine treatment, but also that the cells themselves did not express 
LBP. This suggested that the presence of LBP transcripts in the microarray could have 
come from a non-endothelial cell type (e.g. smooth muscle cells or pericytes) and that 
possibly it was these cells that could be driving the vascular changes. Alternatively, it 
is possible that the microvascular endothelial cells of the retina do express LBP, and 
that in this respect the endothelial cell types tested represent inaccurate models. A 
further possibility is that Müller cells could have been present in the vessel 
preparation, as they express LBP and have specialised ‘end-feet’ connections with the 
vasculature [73, 162]. However when Müller cells were treated with LBP + adenosine 
we found there was no increase in VEGF expression. These observations suggested to 
us that LBP was not affecting vascular behaviour through induction of the TLR-A2aR 
angiogenic switch pathway. 
 
The current literature reports LBP inducing physiological inflammatory effects only 
when in partnership with LPS, however our experimental approach provides evidence 
that LBP is able to elicit a change in vascular behaviour and signal independently of 
LPS, suggesting the existence of an alternate signalling mechanism. In vitro cell 
culture techniques have demonstrated that whilst LBP in complex with LPS is able to 
induce ikßα phosphorylation and p65 nuclear translocation, LBP treatment alone does 
not. However we have shown that exogenously added LBP is able to induce protein 
tyrosine phosphorylation and phospho-ERK signalling in cultured endothelial and 
Müller cells, and LPS appears to inhibit this activation. In three distinct angiogenesis 
assays; Matrigel, aortic ring and metatarsal we observed that exogenously added LBP 
was able to increase vascular growth. Again, we found that LPS inhibited this effect, 
and that when combined with VEGF, LBP had an additive effect. These observations 
support a novel angiogenic function for LBP and imply the activation of different 
signalling mechanisms being initiated by LBP when it is applied alone as opposed to 
being bound to LPS. 
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HUVEC have been reported to alter their protein expression profile as they are 
passaged in culture (e.g. CD14 expression is known to decrease dramatically beyond 
passage 5) [168], therefore our experiments employed HUVEC at a low passage (P2-
4) number so that artefacts arising from loss of gene expression were minimised. 
However, when we used older (P12) HUVEC in the Matrigel assay we found they 
were no longer responsive to LBP, this was an interesting observation suggesting that 
a protein (or proteins) that had been down-regulated during passage were required for 
the LBP-induced effect. After RT-PCR analysis we identified SDC2 as being the only 
member of the TLR, Glypican and Syndecan families to be down-regulated in 
HUVEC as they aged. Thus HUVEC that express SDC2 respond to LBP whereas 
those that do not, don’t. Although this is only circumstantial evidence that SDC2 is 
required for a response to LBP, this notion was supported by preliminary data in Hela 
cells, in which SDC2 knock down led to failure to generate a phospho-ERK response 
to LBP.  
 
HSPGs have been reported to have a wide range of ligand types including growth 
factors and cytokines. SDCs and GPCs are transmembrane HSPG sub-families [203, 
204]. BPI, like LBP, also binds to LPS and activates inflammatory signalling through 
TLRs. In 2007 BPI was found to be able to signal independently of LPS, inducing 
phospho-ERK responses in RPE through the HSPG, GPC6. LBP and BPI share 45% 
sequence homology and are predicted to have the same two-hinge structure [124, 138],  
therefore as HSPGs are known to mediate their ligand activity via the divergence in 
their heparan sulfate (HS) side chains, it is clearly plausible that two similar proteins 
such as LBP and BPI act via the same family of receptors, i.e. BPI through GPC6 and 
LBP possibly via SDC2.  
 
SDC2 is a widely expressed HSPG, which has been shown to have altered expression 
in cancer [208, 209] and is involved in the promotion of sprouting angiogenesis in 
zebra fish [181]. SDC2 has been shown to interact with fibronectin, an extracellular 
matrix protein important for wound healing, migration and differentiation [209, 210]. 
This interaction occurs via the second heparin-binding domain within fibronectin and 
it has been reported that blocking this interaction via ligands such as tenascin-C (a 
large extracellular protein up-regulated in many cancers) enhances cell migration [217, 
218]. If LBP was able to bind to SDC2 and perhaps inhibit its interaction with 
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fibronectin, thus un-anchoring endothelial cells from their basement attachment, this 
could be one way in which LBP induces vascular growth. Over expression of SDC2 
has also been documented to enhance the migration and invasive nature of melanoma 
cells, with knock-down of SDC2 shown to inhibit this effect [214, 215, 224]. SDC2 
has also been reported to enhance both VEGF and TGFß1 signalling, with some 
groups reporting an induction of intracellular ERK [216, 219] and co-
immunoprecipitation experiments showing that Syndecan-2 associates with TGFß and 
its receptor [219].  
 
As previously discussed in Results Chapter 3 section 4, LBP treatment appears to 
enhance the tyrosine phosphorylation of a 60kDa protein, which through investigation 
via mass spectroscopic analysis of a phosphotyrosine pull-down was identified as 
vimentin. Vimentin is an intermediate filament protein, regarded as a marker for 
mesenchymal transition of endothelial cells [223]  and upon phosphorylation has been 
shown to promote cell migration (albeit through serine phosphorylation, although 
tyrosine phosphorylation may also regulate vimentin) [220, 221]. Targeting 
endothelial expressed vimentin in a mouse model of tumourgenesis was found to 
decrease both tumour growth and microvessel density [219] supporting a role for this 
protein in pathological endothelial behaviour.  
 
SDC2 was identified late in this project so the data obtained on its potential interaction 
with LBP are limited. To irrefutably establish a functional link between LBP, SDC2 
and phospho-ERK signalling will require extensive experimental studies, including 
knock-downs and possibly the generation and analysis of a SDC2 knock out mouse. 
However, from what is known about LBP, SDC2 signalling and the experiments 
undertaken in this thesis, it seems reasonable to hypothesise that an interaction 
between these two proteins may constitute a novel angiogenic signalling pathway. 
 
To conclude, this work has demonstrated that LBP, a protein believed to function only 
as a binding partner for LPS, has a novel signalling role as an angiogenic factor. 
Although the mechanism remains elusive, observations here suggest that LBP 
mediates this effect through engagement of cell surface SDC2, cytoskeletal vimentin 
phosphorylation and downstream signalling via ERK (figure 47). 
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Further investigation would be required to elucidate the signalling mechanisms in 
more detail, unequivocal identification of the 60 and 150kDa phosphotyrosine protein 
bands might be informative, and confirmation of the LBP-SDC2 interaction would be 
essential. A luciferase reporter assay to analyse multiple gene promoters post LBP 
treatment would also be useful in order to link the observation of increased phospho-
ERK to transcriptional activation. It would also be interesting to perform a microarray 
screen on cells and / or tissue samples untreated or treated with LBP to delineate the 
genes activated by LBP in an attempt to gain further insight into the signalling cascade 
behind the observations made in the angiogenic assays.  
 
As with any angiogenic factor, it is interesting to consider the therapeutic potential of 
targeting LBP. In this case, blocking LBP function may be risky due to its 
fundamental role in bacterial recognition and innate immunity. Thus, systemic 
inhibition of LBP may not be viable, however due to the immune privileged nature of 
the eye local inhibition of LBP within the retina could be a possible treatment option. 
This would result in a narrow use for a hypothetical drug in treating only ophthalmic 
vascular disease but if, as this thesis work suggests, LBP is a major promoter of retinal 
pathogenesis then it could be beneficial. Alternatively, should future work clarify the 
signalling mechanism then it may be that accessory molecules are identified that may 
be targeted. In fact the syndecan HSPGs are starting to be considered as potential drug 
targets for disease  [214]. It is interesting that we observed an increase in LBP 
expression in the VLDLR-/- mouse at P4 and P8, prior to onset of vascular 
abnormalities. This could suggest that LBP also has the potential to be used as a 
diagnostic marker, although it would prove difficult to separate an observed up 
regulation in LBP being due to the pre-angiogenic priming of a tissue as opposed to 
the up regulation of LBP observed during infection [225].  
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Figure 47: LBP Signalling Schematic. Our data have shown that LBP is able to activate 
signalling in HUVEC and MIO-M1 Muller cells to induce protein tyrosine phosphorylation (e.g. 
vimentin), phospho-ERK, TGFß1 and VEGF expression, with some speculation that the syndecan-
2 HSPG is the LBP receptor. Syndecan-2 has been reported to interact with TGFß receptor 1 and 2 
and has been shown to potentiate VEGF-A signalling. This schematic illustrates how LBP could 
mediate syndecan-2 activation to promote vascular growth.  
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